As filed with the U.S. Securities and Exchange Commission on March 17, 2026.

Registration No. 333-289936

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

____________________________________________

AMENDMENT NO. 6 To

FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

____________________________________________

Farlong Holding Corporation
(Exact name of registrant as specified in its charter)

____________________________________________

Nevada		2833		99-1138388
(State or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Code Number)		(I.R.S. Employer Identification Number)

4010 Valley Blvd, Suite 101
Walnut, California 91789
(909) 468-9215
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

____________________________________________

Simon Cheng
Interim Chief Executive Officer
Farlong Holding Corporation
4010 Valley Blvd, Suite 101
Walnut, California 91789
(909) 468-9215
(Name, address, including zip code, and telephone number, including area code, of agent for service)

____________________________________________

Copies to:

Ying Li, Esq.

Warren Wang, Esq.

Hunter Taubman Fischer & Li LLC

950 Third Avenue, 19th Floor

New York, NY 10022

(212) 530-2206

Fang Liu, Esq.

VCL Law LLP

1945 Old Gallows Road, Suite 260

Vienna, VA 22182

(703) 919-7285

____________________________________________

Approximate date of commencement of proposed sale to the public: Promptly after the effective date of this registration statement.

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

Table of Contents

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities nor may we accept offers to buy these securities until the registration statement filed with the U.S. Securities and Exchange Commission becomes effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS

SUBJECT TO COMPLETION, DATED MARCH 17, 2026

4,000,000 Shares of Common Stock

Farlong Holding Corporation

This is a firm commitment initial public offering of shares of common stock of Farlong Holding Corporation, par value $0.0001 per share.

Prior to this offering, there has been no public market for our common stock. It is currently estimated that the initial public offering price per share will be $4.00 per share. We have reserved the symbol “AFA” for purposes of listing our common stock on the Nasdaq Capital Market (“Nasdaq”) and have applied to list our common stock on Nasdaq. At this time, Nasdaq has not yet approved our application to list our common stock. The closing of this offering is conditioned upon Nasdaq’s final approval of our listing application, and there is no guarantee or assurance that our common stock will be approved for listing on Nasdaq.

Additionally, we are, and following the completion of this offering will continue to be, a “controlled company” as defined under Nasdaq Marketplace Rules 5615(c). Our shareholders prior to the completion of this offering, KML Family Trust and KMA Trust, will hold 72.7% and 18.2% of our issued and outstanding shares of common stock, respectively, immediately after the consummation of this offering, assuming the sale of 4,000,000 shares of common stock we are offering, and no exercise of the underwriters’ over-allotment option. As a result, Karin Mei Huang, as the beneficial owner of the shares held by KMA Trust and KML Family Trust, will be able to exercise 90.9% of the aggregate voting power of our issued and outstanding shares of common stock and will be able to determine all matters requiring approval by our stockholders, immediately after the consummation of this offering. For further information, see “Principal Stockholders.” We do not intend to avail ourselves of the corporate governance exemptions afforded to a “controlled company” under the Nasdaq Marketplace Rules. However, our decision not to rely on the “controlled company” exemption could change. See “Risk Factors” and “Management — Controlled Company.”

We are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. See “Prospectus Summary — Implications of Being an Emerging Growth Company.”

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 10 of this prospectus.

	Per Share	Total Without Over-Allotment Option	Total With Over-Allotment Option
Initial public offering price of common stock	$	$	$
Underwriters’ discounts(1)	$	$	$
Proceeds to our company before expenses(2)	$	$	$

____________

(1) Represents underwriting discounts equal to 6.5% per share of common stock. See “Underwriting” for additional information regarding total underwriter compensation.

(2) We have granted the underwriters an option for a period of 45 days after the closing of this offering to purchase up to 15% of the total number of shares of common stock to be offered by us pursuant to this offering (excluding shares of common stock subject to this option), solely for the purpose of covering over-allotments, if any, at the public offering price less the underwriting discounts. If the underwriters exercise the option in full, the total underwriting discounts payable will be $1,196,000, based on an assumed public offering price of $4.00 per share of common stock, and the total gross proceeds to us, before underwriting discounts and expenses, will be $18,400,000. See “Expenses Relating to this Offering” for the total estimated expenses related to this offering.

Neither the U.S. Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

The underwriters expect to deliver the shares of common stock against payment as set forth under “Underwriting,” on or about [ ], 2026.

Sole Book-Running Manager

US Tiger Securities, Inc.

The date of this prospectus is , 2026.

Table of Contents

TABLE OF CONTENTS

		Page
About This Prospectus		ii
Prospectus Summary		1
The Offering		8
Risk Factors		10
Disclosure Regarding Forward-Looking Statements		37
Use of Proceeds		38
Dividend Policy		39
Capitalization		40
Dilution		41
Management’s Discussion and Analysis of Financial Condition and Results of Operations		42
Business		53
Management		78
Executive and Director Compensation		85
Certain Relationships and Related Party Transactions		88
Security Ownership of Certain Beneficial Owners and Management		91
Description of Capital Stock		93
Shares Eligible for Future Sale		97
Underwriting		99
Legal Matters		103
Experts		103
Where You Can Find More Information		103
Index to Consolidated Financial Statements		F-1

Table of Contents

About This Prospectus

No dealer, salesperson, or other individual has been authorized to give any information or to make any representation other than those contained in this prospectus in connection with the offer made by this prospectus and, if given or made, such information or representations must not be relied upon as having been authorized by us. You should rely only on the information contained in this prospectus or in any related free writing prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so, or to any person to whom it is unlawful to make such offer or solicitation.

For investors outside the United States: We and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside the United States.

Our logo and some of our trademarks and tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames, and service marks that are the property of others. Solely for convenience, trademarks, tradenames, and service marks referred to in this prospectus may appear without the ®, ™, and SM symbols. References to our trademarks, tradenames, and service marks are not intended to indicate in any way that we will not assert to the fullest extent under applicable law our rights or the rights of the applicable licensors if any, nor that respective owners to other intellectual property rights will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

The market data and certain other statistical information used throughout this prospectus are based on independent industry publications, reports by market research firms, or other independent sources that we believe to be reliable sources; and we have not commissioned any of the market or survey data that is presented in this prospectus. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe these industry publications and third-party research surveys, and studies are reliable. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section entitled “Risk Factors” beginning on page 10 of this prospectus. These and other factors could cause our future performance to differ materially from our assumptions and estimates. Some market and other data included herein, as well as the data of competitors as they relate to Farlong Holding Corporation, is also based on our good faith estimates. See “Cautionary Note Regarding Forward-Looking Statements.”

Certain Definitions

Unless otherwise indicated or the context requires otherwise, references in this prospectus to:

• “City of Hope” are to Beckman Research Institute of the City of Hope, a California non-profit public benefit corporation;

• “Exchange Act” are to the Securities Exchange Act of 1934, as amended;

• “Farlong,” “we,” “us,” “our,” “our Company,” and the “Company” are to Farlong Holding Corporation, and its consolidated subsidiaries, as the case may be;

• “Longstar” are to Longstar Healthpro, Inc., formerly known as Longstar International Inc., a California corporation which is wholly owned by the Company and doing business as Farlong Pharmaceutical and Farlong Nutraceutical;

• “OEM white-label” are to contracted product development and cGMP manufacturing based on our proprietary formulations and specifications, where (i) finished goods are produced by a third-party manufacturer, (ii) products are packaged under the customer’s brand labels, and (iii) branding and downstream marketing are owned and managed by the customer;

Table of Contents

• “pre-registered healthcare providers” are to clinicians whose contact information and professional credentials have been entered into our DirecTCM platform — either because they (i) created an account themselves, (ii) were invited by a distributor, or (iii) were imported during bulk onboarding of a clinic or hospital group. Pre-registration does not mean that the provider is actively using the platform;

• “SEC” or the “Commission” are to the United States Securities and Exchange Commission;

• “Securities Act” are to the Securities Act of 1933, as amended;

• “SKUs” are to stock keeping units. SKUs refers to the total sellable units we offered in the fiscal year after accounting for multiple package sizes, capsule counts, and brand labels for the underlying finished product formulations. For example, the Muscle REx BioPrecision formulation appears as five separate SKUs (five brand labels), and each of the legacy formulations likewise may have one or more SKUs depending on the packaging size; and

• “U.S. dollars,” “$,” and “dollars” are to the legal currency of the United States.

Glossary of Industry Terms

The following are abbreviations, acronyms, and definitions of certain terms used in this document, which are commonly used in our industry:

“cGMP” means current good manufacturing practice regulations promulgated by the FDA under the authority of the FFFDCA. These regulations, which have the force of law, require that manufacturers, processors, and packagers of drugs, medical devices, dietary supplements, some food, and blood take proactive steps to ensure that their products are safe, pure, and effective.

“DSHEA” means the Dietary Supplement Health and Education Act of 1994, which amended the FFDCA to establish a framework governing the composition, safety, labeling, manufacturing, and marketing of dietary supplements.

“EPA” means the U.S. Environmental Protection Agency.

“FDA” means the U.S. Food and Drug Administration.

“FFDCA” means the Federal Food, Drug and Cosmetic Act, which is a set of U.S. laws passed by Congress in 1938 giving authority to the FDA to oversee the safety of food, drugs, medical devices, and cosmetics.

“FSMA” means the FDA Food Safety Modernization Act.

“FTC” means the U.S. Federal Trade Commission.

“FTC Act” means the Federal Trade Commission Act.

“GRAS” means Generally Recognized As Safe.

“HIPAA” means the Health Insurance Portability and Accountability Act of 1996, which has the goal of making it easier for people to keep health insurance, protect the confidentiality and security of healthcare information and help the healthcare industry control administrative costs.

“Individually identifiable health information” is defined by HIPPA to mean information that is a subset of health information, including demographic information collected from an individual, and: (1) is created or received by a health care provider, health plan, employer, or health care clearinghouse; and (2) relates to the past, present, or future physical or mental health or condition of an individual; the provision of health care to an individual; or the past, present, or future payment for the provision of health care to an individual; and (a) that identifies the individual; or (b) with respect to which there is reasonable basis to believe the information can be used to identify the individual.

“Mg” means milligrams.

“OFCR” means the Office for Civil Rights of the U.S. Department of Health and Human Services, which administers the privacy aspects of HIPAA.

“PII” means personal identifiable information.

“TCM” means Traditional Chinese Medicine, which is a holistic health system developed over thousands of years, focusing on using natural, plant-based herbal formulations to support wellness. TCM aims to enhance health through a natural, plant-based approach.

iii

Table of Contents

Prospectus Summary

This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our common stock. You should read this entire prospectus carefully, including the “Risk Factors” section and our historical financial statements and the notes thereto, each included elsewhere in this prospectus, before deciding whether to buy our common stock.

Overview

Our Company

We are a science-driven healthcare and wellness company pioneering innovative solutions and personalized health approaches. Our vertically integrated brands provide actionable insights and personalized healthcare data, products, and services to help individuals proactively improve and maintain their health.

We are dedicated to providing authentic and personalized health solutions that meet a high standard of quality and consumer trust. We work to empower individuals with the knowledge, tools, and solutions needed to lead a life of optimal health and wellness.

Founded on the principles of combining traditional herbal knowledge with contemporary scientific techniques, we are working toward self-affirmed GRAS conclusions for the principal botanical ingredients used in our dietary supplement line. Under the FFDCA, a substance is GRAS for a particular use when qualified experts conclude that the substance is safe under the conditions of its intended use, and that conclusion is supported by publicly available scientific evidence. The FDA does not “approve” GRAS status; instead, a company may (i) self-affirm that its ingredient is GRAS or (ii) voluntarily submit a GRAS notice for FDA review. To date, we have employed the self-affirmation pathway for the following ingredients, each of which is present in one or more of our BioPrecision supplements:

• Notoginseng (Panax notoginseng) saponin extract;

• Breviscapine (Erigeron breviscapus) flavonoid extract;

• Polygonum capitatum extract;

• Innerpure formulation; and

• Rodgersia sambucifolia Hemsl. Extract.

Self-affirmation has been completed with the assistance of independent toxicologists and in accordance with FDA guidance; however, the FDA has not reviewed nor confirmed these GRAS conclusions. No other ingredients or finished products in our current portfolio have been evaluated under the GRAS framework, and none of our products are the subject of an FDA “no-questions” letter. Our products are dietary supplements which are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

The small-scale, preclinical studies we sponsor are being run entirely outside the purview of the U.S. FDA’s investigational-drug framework:

• they do not involve the administration of an “investigational new drug”;

• they are not being conducted pursuant to an Investigational New Drug Application (“IND”);

• we have not filed, and do not presently intend to file, an IND or any other drug-related submission with the FDA; and

• the studies are not designed to serve as, or to be included in, an FDA drug-approval dossier.

Table of Contents

Accordingly, while our finished products must comply with the DSHEA and the FFDCA, none of our products described in this prospectus are regulated by the FDA as prescription or over-the-counter drugs. Our regulatory objective is limited to marketing our formulations in the United States as dietary supplements, for which “FDA approval” is neither required nor available. Therefore, we have not submitted an IND to the FDA nor liaised with the FDA in relation to any trials conducted as of the date of this prospectus and none of our products is regulated by the FDA.

Our current distribution channels consist of (i) our DirecTCM platform; (ii) online stores through our official website and various e-commerce websites, such as Amazon.com, TikTok, and Walmart.com; and (iii) B2B wholesale in the clinics or medicine centers, and OEM specialist sales lines, such as the franchise centers. We also provide OEM White Label services to select customers who sell our formulations under their own brands.

Our DirecTCM platform was officially launched in May 2025. As of December 31, 2025, our DirecTCM platform had approximately 30,000 pre-registered healthcare providers. We had 108 active healthcare providers on our DirecTCM platform as of December 31, 2025, which accounted for 0.36% of all pre-registered healthcare providers on our DirecTCM platform. The active healthcare providers refer to those healthcare providers who logged into our DirecTCM platform more than one time in the past 92 days (from October 1, 2025 to December 31, 2025) and used at least one clinical-decision or ordering feature on our DirecTCM platform as of December 31, 2025. As of December 31, 2025, the DirecTCM platform had 65 healthcare providers enrolled in the pilot VIP membership program we launched in June 2025. See “Business — Recent Development.”

According to an optional self-reported survey on our DirecTCM platform, the active healthcare providers each see a median of 20 patients per day, roughly 420 patients per month. Therefore, 108 active healthcare providers in total represent an estimated 45,360 patients encountered per month. Our DirecTCM platform began generating revenue following its commercial launch in October 2025. For the three months ended December 31, 2025, our DirecTCM platform generated revenue from orders initiated directly through the platform, including orders placed by healthcare providers and by patients using healthcare provider generated codes. As the DirecTCM platform remained in the early stages of commercialization, revenue generated through the platform during the three months ended December 31, 2025 consisted of $13,971 of order-based revenue and $1,527 of subscription revenue from the pilot VIP membership program, for total DirecTCM platform revenue of $15,498. In addition, subscription revenue from 65 healthcare providers participating in the pilot VIP membership program is recognized ratably over the duration of each membership period. For the fiscal year ended September 30, 2025, prior to commercialization, the DirecTCM platform did not generate revenue.

Our Strengths

We believe the following strengths are essential for our success and differentiate us from our competitors:

• Proprietary technology and intellectual property;

• Established brand;

• Large and growing customer base;

• Experienced management team with strong financial expertise; and

• Innovative culture, and research and development (“R&D”) capabilities.

Growth Strategies

We intend to develop our business and strengthen our brand loyalty by implementing the following strategies:

• Expansion plans on DirecTCM platform and products;

• Investment in technology and R&D; and

• Plans for growing our business.

Table of Contents

Organizational Structure

We were incorporated under the laws of the State of Nevada as a corporation in October 2023. For more details on our corporate history, please refer to “Business — Corporate History and Structure.”

The following diagram illustrates our corporate structure as of the date of this prospectus and upon completion of our initial public offering (“IPO”) based on a proposed number of 4,000,000 shares of common stock being offered, assuming no exercise of the underwriters’ over-allotment option.

____________

Note:

(1) Represents 8,000,000 shares of our common stock held by KMA Trust as of the date of this prospectus. The trustee of KMA Trust is Karin Mei Huang.

(2) Represents 32,000,000 shares of our common stock held by KML Family Trust as of the date of this prospectus. The trustees of KML Family Trust are Karin Mei Huang and her husband, Lipin Zeng.

Corporate Information

Our principal executive office is located at 4010 Valley Blvd, Suite 101, Walnut, California 91789. Our telephone number is (909) 468-9215 and our principal website addresses are www.Farlong.com and www.DirecTCM.com. The information contained in, or that can be accessed through, our websites is not incorporated by reference into, and is not part of, this prospectus.

Summary of Risk Factors

Investing in our common stock involves significant risks. You should carefully consider all of the information in this prospectus before making an investment in our common stock. Below please find a summary of the principal risks we face, organized under relevant headings. These risks are discussed more fully in the section titled “Risk Factors.”

Operational Risks (for a more detailed discussion, see “Risk Factors — Operational Risks” beginning on page 10 of this prospectus)

Risks and uncertainties related to our operations include, but are not limited to, the following:

• We have had significant accumulated deficits as of December 31, 2025, which raises substantial doubt about our ability to continue as a going concern (see page 10 of this prospectus);

Table of Contents

• We will need additional capital, which may not be available on commercially acceptable terms, if at all (see page 10 of this prospectus);

• Our operating results may vary considerably in the future, making it challenging to forecast our future performance and potentially causing our results to fall short of expectations or any guidance we provide (see page 11 of this prospectus);

• Failing to maintain high-quality standards for our products and services could harm our business and damage our reputation (see page 12 of this prospectus);

• A significant amount of our revenue and purchases have historically been due to only a small number of customers and vendors, respectively, and if we were to lose any material customer or vendor, our results of operations could be adversely affected (see page 12 of this prospectus);

• Customer demand is difficult to forecast accurately, and as a result we may be unable to make planning and spending decisions to match such demand (see page 12 of this prospectus);

• A significant amount of our revenue has been derived from the sale of products on Amazon and TikTok. Any limitation or restriction, temporarily or otherwise, to sell on Amazon’s and TikTok’s platforms could have a material adverse impact to our business, results of operations, financial condition, and prospects (see page 13 of this prospectus);

• Increases in ingredient costs, long lead times, supply shortages, and changes could disrupt our supply chain and negatively impact our business, financial condition, and operating results (see page 13 of this prospectus);

• We may allocate our limited resources to pursue particular products or services and may fail to capitalize on products or services that may be more profitable or for which there is a greater likelihood of success (see page 13 of this prospectus);

• We may be subject to inventory spoliation (see page 13 of this prospectus);

• Failure to renew our current leases or locate desirable alternatives for our facilities could materially and adversely affect our business (see page 14 of this prospectus);

• In the future, we may need licenses for third-party technology that could be unavailable or only offered on commercially unreasonable terms, potentially increasing our costs or causing unforeseen adverse effects (see page 14 of this prospectus);

• Due to the high costs and uncertainty of litigation, we may not be able to enforce our intellectual property rights against third parties (see page 14 of this prospectus);

• We may struggle to partner with others for technological advancements and new products and services (see page 14 of this prospectus);

• Our use of “open source” software could subject our proprietary software to general release, hinder our product sales, and expose us to potential litigation (see page 14 of this prospectus);

• Our business is exposed to risks associated with credit card and other online payment chargebacks and fraud (see page 15 of this prospectus);

• We face risks associated with our return policy and warranty (see page 15 of this prospectus);

• Our use of clinical studies presents inherent risks (see page 16 of this prospectus);

• Our business depends on our brands, and any failure to maintain, protect, or enhance our brands, including as a result of events outside our control, could materially and adversely affect our business, financial condition, and results of operations (see page 16 of this prospectus);

• We source ingredients for our products from foreign suppliers and face risks related to international trade and importation (see page 17 of this prospectus);

Table of Contents

• A substantial portion of our sales relies on distributors and health professionals, over whom we have limited control. If these relationships deteriorate, or if these parties fail to sell our products, harm our reputation, or fail to comply with regulations, our business, financial condition, and results of operations could be materially and adversely affected (see page 17 of this prospectus);

• We rely upon independent third-party transportation providers for all of our product shipments and are subject to increased shipping costs as well as the potential inability of our third-party transportation providers to deliver on a timely basis (see page 18 of this prospectus);

• Failure to protect our intellectual property rights could adversely affect our business (see page 19 of this prospectus);

• Third parties may claim that we infringe their proprietary intellectual property rights, which could cause us to incur significant legal expenses and prevent us from promoting our products (see page 19 of this prospectus); and

• We recently experienced changes to our board of directors and management. These changes may create uncertainty and, more generally, if we are unable to attract or retain our key personnel, including our executive officers, senior management, and key employees, our ongoing operations and growth could be materially and adversely affected.

Economic, Political, and Market Risks (for a more detailed discussion, see “Risk Factors — Economic, Political, and Market Risks” beginning on page 23 of this prospectus)

Risks and uncertainties related to economic, market, and geopolitical conditions include, but are not limited to, the following:

• We rely on third-party contract manufacturers located in China to produce our supplements, making us highly vulnerable to U.S. tariffs, trade disputes, and other disruptions related to U.S.-China trade relations, which could significantly increase our costs and materially harm our business (see page 23 of this prospectus);

• We face competition in the herbal supplement industry, and we expect competition from existing competitors and other companies that may enter the market or introduce new solutions in the future, which may decrease our net revenue (see page 24 of this prospectus);

• Global economic conditions could materially and adversely affect the Company’s business, financial condition, results of operations and growth (see page 25 of this prospectus); and

• We operate in an industry with the risk of intellectual property litigation. Claims of infringement against us may hurt our business (see page 25 of this prospectus).

Legal, Regulatory, and Compliance Risks (for a more detailed discussion, see “Risk Factors — Legal, Regulatory, and Compliance Risks” beginning on page 25 of this prospectus)

Risks and uncertainties related to legal, regulatory, and compliance include, but are not limited to, the following:

• We are subject to numerous laws and regulations applicable to the herbal supplement industry, which, if we are found to have violated, may materially and adversely affect our business, financial condition, and results of operations (see page 25 of this prospectus);

• Changes in FDA and other regulatory agency policies, or disagreements over our product classifications, could delay or increase the costs of offering our products, impacting our business (see page 26 of this prospectus);

• We and our suppliers must comply with numerous laws and regulations related to the manufacture, sale, and marketing of herbal supplements. Compliance with these laws can increase costs, limit our ability to sell certain products, and expose us to enforcement actions, any of which could materially and adversely affect our business, financial condition, and results of operations (see page 26 of this prospectus);

• Economic downturns or a change in consumer preferences, perception and spending habits could limit consumer demand for our products and negatively affect our future business (see page 28 of this prospectus); and

• Marketing activities for our products are subject to strict governmental regulation which may limit our ability to market or promote such products (see page 28 of this prospectus).

Table of Contents

Common Stock and Trading Risks (for a more detailed discussion, see “Risk Factors — Common Stock and Trading Risks” beginning on page 30 of this prospectus)

In addition to the risks described above, we are subject to general risks and uncertainties relating to this offering and the trading market, including, but not limited to, the following:

• There has been no public market for our common stock prior to this offering, and you may not be able to resell our common stock at or above the price you pay for them, or at all (see page 30 of this prospectus);

• The market price of our common stock may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the initial public offering price (see page 30 of this prospectus);

• The price of our common stock could be subject to rapid and substantial volatility (see page 31 of this prospectus);

• You will experience immediate and substantial dilution in the net tangible book value of common stock purchased in this offering (see page 31 of this prospectus);

• If we fail to implement and maintain an effective system of internal controls or fail to remediate the material weaknesses in our internal control over financial reporting that have been identified, we may fail to meet our reporting obligations or be unable to accurately report our results of operations or prevent fraud, and investor confidence and the market price of our common stock may be materially and adversely affected (see page 31 of this prospectus);

• We will incur substantial increased costs as a result of being a public company (see page 32 of this prospectus);

• If we cannot continue to satisfy the listing requirements and other rules of Nasdaq, our securities may be delisted, which could negatively impact the price of our securities and your ability to sell them (see page 33 of this prospectus)

• Our management has broad discretion to determine how to use the funds raised in the offering and may use them in ways that may not enhance our results of operations or the price of our common stock (see page 33 of this prospectus);

• We will be a “controlled company” within the meaning of the Nasdaq listing rules and are allowed to follow certain exemptions from certain corporate governance requirements that could adversely affect our public stockholders (see page 33 of this prospectus); and

• Anti-takeover provisions in our Articles of Incorporation and our Bylaws, as well as provisions of Nevada law, might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock (see page 35 of this prospectus).

Implications of Being an “Emerging Growth Company”

As a company with less than $1.235 billion in revenue during our last fiscal year, we qualify as an “emerging growth company” as defined in the JOBS Act. An “emerging growth company” may take advantage of reduced reporting requirements that are otherwise applicable to larger public companies. In particular, as an emerging growth company, we:

• may present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations;

• are not required to provide a detailed narrative disclosure discussing our compensation principles, objectives, and elements and analyzing how those elements fit with our principles and objectives, which is commonly referred to as “compensation discussion and analysis”;

• are not required to obtain an attestation and report from our auditors on our management’s assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;

Table of Contents

• are not required to obtain a non-binding advisory vote from our stockholders on executive compensation or golden parachute arrangements (commonly referred to as the “say-on-pay,” “say-on frequency,” and “say-on-golden-parachute” votes);

• are exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and Chief Executive Officer pay ratio disclosure; and

• are eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act.

We intend to take advantage of all of these reduced reporting requirements and exemptions, including the longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act. Our election to use the phase-in periods may make it difficult to compare our financial statements to those of non-emerging growth companies and other emerging growth companies that have opted out of the phase-in periods under §107 of the JOBS Act.

Under the JOBS Act, we may take advantage of the above-described reduced reporting requirements and exemptions until we no longer meet the definition of an emerging growth company. The JOBS Act provides that we would cease to be an “emerging growth company” at the end of the fiscal year in which the fifth anniversary of our initial sale of common equity pursuant to a registration statement declared effective under the Securities Act occurred, if we have more than $1.235 billion in annual revenue, have more than $700 million in market value of our common stock held by non-affiliates, or issue more than $1 billion in principal amount of non-convertible debt over a three-year period.

Controlled Company

Our shareholders prior to the completion of this offering, KML Family Trust and KMA Trust, will hold 72.7% and 18.2% of our issued and outstanding shares of common stock, respectively, immediately after the consummation of this offering, assuming the sale of 4,000,000 shares of common stock we are offering, and no exercise of the underwriters’ over-allotment option. As a result, Karin Mei Huang, as the beneficial owner of the shares held by KMA Trust and KML Family Trust, will be able to exercise 90.9% of the aggregate voting power of our issued and outstanding shares of common stock and will be able to determine all matters requiring approval by our stockholders, immediately after the consummation of this offering. As a result, we will be deemed a “controlled company” for the purpose of the Nasdaq listing rules. As a controlled company, we are permitted to elect to rely on certain exemptions from the obligations to comply with certain corporate governance requirements, including the requirements that:

• a majority of our board of directors consist of independent directors;

• our director nominees be selected or recommended solely by independent directors; and

• we have a nominating and corporate governance committee and a compensation committee that are composed entirely of independent directors with a written charter addressing the purposes and responsibilities of the committees.

Although we do not intend to rely on the controlled company exemptions under the Nasdaq listing rules even if we are a controlled company, we could elect to rely on these exemptions in the future, and if so, you would not have the same protection afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. See “Risk Factors” and “Management — Controlled Company.”

Table of Contents

The Offering

Common stock we are offering		4,000,000 shares (or 4,600,000 shares if the underwriters exercise their over-allotment option in full)
Price per share		We currently estimate that the initial public offering price will be $4.00 per share of common stock.
Over-allotment option		We have granted to the underwriters an option to purchase up to an additional 600,000 shares of common stock (equal to 15% of the number of shares of common stock sold in the offering) from us, solely to cover over-allotments, if any, at the applicable public offering price less the underwriting discounts shown on the cover page of this prospectus. The underwriters may exercise this option in full or in part at any time and from time to time until 45 days after the date of this prospectus.
Common stock outstanding immediately before this offering		40,000,000 shares
Common stock outstanding immediately after this offering		44,000,000 shares, or 44,600,000 shares if the over-allotment option is exercised in full
Use of proceeds		We expect to receive net proceeds from this offering of approximately $14.5 million (or approximately $16.6 million if the underwriters exercise in full their option to purchase 600,000 additional shares of our common stock), assuming an initial public offering price of $4.00 per share, and after deducting underwriting discounts, non-accountable expense allowance, and estimated offering expenses. We currently intend to use the net proceeds we receive from this offering for general corporate purposes, including working capital, R&D, financing our marketing and operational expenses, upgrading our Company’s infrastructure, and international expansion.
Risk Factors		The purchase of our common stock involves a high degree of risk. The common stock offered in this prospectus is for investment purposes only and currently no market exists for our common stock. Please refer to the section entitled “Risk Factors” before making an investment in our common stock.
Lock-up		We have agreed, subject to certain exceptions, not to transfer or dispose of, directly or indirectly, any of our common stock, or any securities convertible into or exchangeable or exercisable for our common stock, for a period of six months from the closing of this offering.
		Our directors, executive officers, and principal stockholders (defined as owners of 5% or more of our common stock) have agreed, subject to certain exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase, or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of our common stock or such other securities for a period of six months following the closing of this offering, without the prior written consent of the Representative. See “Underwriting” for more information.

Table of Contents

Proposed trading symbol		We have applied to list our common stock for trading on Nasdaq under the symbol “AFA.” The approval of our listing on Nasdaq is a condition of closing this offering. However, no assurance can be given that our application will be approved and that our common stock will ever be listed on Nasdaq. If our application is not approved by Nasdaq, we will not be able to consummate the offering and will terminate the offering.
Transfer agent		Transhare Corporation

Unless we indicate otherwise, all information in this prospectus:

• is based on 40,000,000 shares of common stock issued and outstanding as of the date of this prospectus; and

• assumes no exercise by the underwriters of their option to purchase up to 600,000 additional shares of common stock to cover over-allotments, if any.

Table of Contents

Risk Factors

An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should consider carefully the risks described below, together with all of the other information set forth in this prospectus, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes. If any of these risks actually occurs, our business, financial condition, results of operations, or cash flow could be materially and adversely affected, which could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. The risks described below and discussed in other parts of this prospectus are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business. You should only consider investing in our common stock if you can bear the risk of loss of your entire investment.

Operational Risks

We have had significant accumulated deficits as of December 31, 2025, which raises substantial doubt about our ability to continue as a going concern.

We have experienced recurring losses from operations and negative cash flows from operating activities since 2022. For the three months ended December 31, 2025 and 2024, we recorded net losses of $700,240 and $403,059, respectively. Our accumulated deficit and negative operating cashflow amounted to $7,339,948 and $600,245 for the three months ended December 31, 2025, respectively, and $6,639,708 and $480,559 for the three months ended December 31, 2024, respectively.

Management has determined that these conditions raise substantial doubt about our ability to continue as a going concern. The ability to continue as a going concern is dependent on us obtaining adequate capital to fund operating losses until we become profitable. If we are unable to obtain adequate capital, we could be forced to cease or reduce our operations. Our consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty. If we are unable to manage our business to have sufficient funds to operate within the normal operating cycle of a 12-month period, we may have to consider certain cost cutting measure to reduce our operating costs. We may also consider supplementing our available sources of funds through the issuance of additional debt and equity financing.

We can make no assurances that required financings will be available for the amounts needed, or on terms commercially acceptable to us, if at all. If one or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there will likely be a material adverse effect on us and it will materially and adversely affect our ability to continue as a going concern. As a result, investors or other financing sources may be unwilling to provide funding to us on commercially reasonable terms or at all.

Further, if we are unable to continue as a going concern, we may have to discontinue operations and liquidate our assets and may be compelled to receive less than the value at which those assets are carried on our consolidated audited financial statements, which would cause the stockholders to lose all or a part of their investment.

We will need additional capital, which may not be available on commercially acceptable terms, if at all.

We need capital to support our operations and to expand our production capacity, develop new products, and enhance our marketing efforts. For the three months ended December 31, 2025 and the fiscal years ended September 30, 2025 and 2024, we recorded net losses of $700,240, $2,555,522, and $1,955,962, respectively. We may also require additional funding in the future to support our operations, expand our product line, pay expenses, or expand or complete acquisitions. The most likely source of future funds presently available to us will be through the sale of equity capital or debt. Any sale of equity capital will result in dilution to existing stockholders. Furthermore, we may incur debt in the future, and may not have sufficient funds to repay our future indebtedness or may default on our future debts, jeopardizing our business viability.

Table of Contents

We may not be able to borrow or raise additional capital in the future to meet our needs or to otherwise provide the capital necessary to expand our operations and business, which may result in the value of our securities decreasing in value or becoming worthless. Additional financing may not be available to us on terms that are acceptable or at all. Consequently, we may not be able to proceed with our intended business plans. Obtaining additional financing contains risks, including:

• additional equity financing may not be available to us on satisfactory terms and any equity we are able to issue could lead to dilution for current stockholders;

• loans or other debt instruments may have terms and/or conditions, such as interest rates, restrictive covenants, and control or revocation provisions, which are not acceptable to management or our directors;

• the current environment in capital markets combined with our capital constraints may prevent us from being able to obtain adequate debt financing;

• if we fail to obtain required additional financing to commercialize our products and grow our business, we would need to delay or scale back our business plan, reduce our operating costs, or delay product launches, each of which would have a material adverse effect on our business, future prospects, and financial condition.

Additionally, we may have difficulty obtaining additional funding, and we may have to accept terms that would adversely affect our stockholders. For example, the terms of any future financings may impose restrictions on our right to declare dividends (provided that none are currently planned) or on the manner in which we conduct our business. Additionally, lending institutions or private investors may impose restrictions on a future decision by us to make capital expenditures, acquisitions, or significant asset sales. If we are unable to raise additional funds, we may be forced to curtail or even abandon our business plan.

Our operating results may vary considerably in the future, making it challenging to forecast our future performance and potentially causing our results to fall short of expectations or any guidance we provide.

Quarterly and annual fluctuations in our operating results can make future predictions difficult, and these variations may arise from numerous factors beyond our control, including but not limited to:

• our capacity to successfully bring our products and services to market within our expected timelines;

• the timing, cost, and level of investment in new marketing initiatives, R&D, and commercialization activities related to our products and services, which may vary over time;

• our ability to promote and drive adoption of our products and services within the herbal supplement market, and our capability to expand into new target markets or geographical areas;

• the prices at which we can effectively sell our products and services;

• the timing and amount of expenditures required to develop, commercialize, or acquire additional products, expand our facilities, or enter new geographical regions;

• the seasonal spending patterns of our customers;

• any new laws and regulations that may apply to us;

• any new tariffs that may apply to us;

• future accounting standards or changes in our accounting policies;

• the results of any future litigation or government investigations involving us or our industry;

• the status of inflation and interest rates on the economy, investment in the herbal supplement industry, and our business operations, as well as the resources and operations of our customers, suppliers, and distributors; and

• general industry, economic, and market conditions, along with other factors that may be unrelated to our operating performance or that of our competitors.

Table of Contents

Failing to maintain high-quality standards for our products and services could harm our business and damage our reputation.

Our products, including herbal supplements, may have defects or errors that prevent them from performing as intended. These issues could lead to recalls, market withdrawals, negative publicity, and damage to our reputation. This may result in customer loss, revenue decline, refunds, cancellations, subscription terminations, and reduced market acceptance. Our DirecTCM’s services also rely on third-party testing and physician interpretation, which may contain undetected defects or errors, potentially leading to inaccurate recommendations.

As our technology usage grows, we face increased scrutiny and liability risks, especially in the event we experience data breaches or platform failures. Addressing these issues may divert significant resources. Additionally, integrating acquired technologies can be challenging and may not meet our quality standards.

The indemnification terms we entered into with customers and third parties may result in substantial liability, sometimes with uncapped and enduring obligations. Our general liability insurance may not be sufficient to cover these claims, leading to potential financial strain. Disputes over such obligations could harm our relationships, reputation, and platform demand, potentially materially and adversely affecting our business, results of operations, and financial condition.

A significant amount of our revenue and purchases have historically been due to only a small number of customers and vendors, respectively, and if we were to lose any material customer or vendor, our results of operations could be adversely affected.

For the three months ended December 31, 2025, Long Far Herbal Medicine Mfg. (HK) Limited accounted for 10% of our total revenue. For the fiscal year ended September 30, 2025, ZenLife Herb Company (“Zenlife”) accounted for 21% of our total revenue. For the fiscal year ended September 30, 2024, our two largest customers, ZenLife and Dr. ChunHua Cui accounted for 25% and 12% of our total revenue, respectively. For an example of a typical transaction, see “Business — Our Customers.” We may lose a significant customer due to a variety of factors, including our ability to provide quality products and services. Even though we have a strong record of performance, we cannot guarantee that we will continue to maintain the business cooperation with these significant customers at the same level, or at all. If any significant customer terminates its relationship with us, we cannot assure you that we will be able to secure an alternative arrangement with comparable customers in a timely manner, or at all. Losing one or more of these significant customers could adversely affect our revenue and profitability.

In addition, we depend upon a few significant suppliers that accounted for more than 10% of our total purchases for the past two fiscal years. For the three months ended December 31, 2025, our three largest vendors, Zenlife, TCM Product Inc, and Yunnan Panlong Yunhai Pharmaceutical Trading Co., Ltd (“Yunnan Panlong Trading”) accounted for 73%, 16%, and 11% of our total purchases, respectively. For the fiscal year ended September 30, 2025, our five largest vendors, Kunming Aoqun Bio-Tech Co., Ltd. (“Kunming Aoqun”), TCM Product Inc, Zenlife, Yunnan Panlong Trading, and Lonza Greenwood LLC accounted for 44%, 18%, 16%, 11%, and 10% of our total purchases, respectively. For the fiscal year ended September 30, 2024, two vendors, Kunming Aoqun and TCM Product Inc., accounted for 83% and 11% of our total purchases, respectively. We cannot ensure that we will have no concentration of suppliers in the future. Such third-party suppliers are run by independent entities that are subject to their own unique operational and financial risks, which are beyond our control. If such significant suppliers breach or terminate their contracts with us, or experience significant disruptions to their operations, we will be required to find and enter into arrangements with one or more replacement suppliers. Finding alternative suppliers could involve significant delays and other costs and these suppliers may not be available to us on reasonable terms or at all. As a result, this could materially and adversely affect our business, results of operations, and financial results, and result in lost or deferred revenue.

Customer demand is difficult to forecast accurately, and as a result we may be unable to make planning and spending decisions to match such demand.

We make planning and spending decisions, including capacity expansion, procurement commitments, personnel needs, and other resource requirements based on our estimates of customer demand. A significant portion of our revenue is derived from customers who purchase our herbal supplements. Therefore, our customer demand may be impacted by factors out of our control, such as unexpected shifts in the preferences of U.S. consumers that could adversely impact our customers’ costs and pricing strategies. Failure to meet customer demand in a timely fashion or at all may materially and adversely affect our business, results of operations, and financial condition.

Table of Contents

A significant amount of our revenue has been derived from the sale of products on Amazon and TikTok. Any limitation or restriction, temporarily or otherwise, to sell on Amazon’s and TikTok’s platforms could have a material adverse impact to our business, results of operations, financial condition, and prospects.

For the three months ended December 31, 2025, approximately 27% and 4% of our revenue was derived from the sale of products on Amazon and TikTok, respectively. For the fiscal year ended September 30, 2025, approximately 17% and 17% of our revenue was derived from the sale of products on Amazon and TikTok, respectively. We are subject to Amazon’s and TikTok’s terms of service and various other Amazon and TikTok seller policies that apply to third parties selling products on Amazon’s and TikTok’s marketplaces. Amazon’s and TikTok’s terms of service provide, among other things, that they may terminate or suspend the agreement with any seller or any of the services being provided to a seller at any time and for any reason. In addition, if Amazon or TikTok determines that any seller’s actions or performance, including ours, may result in violations of their terms or policies, or create other risks to Amazon, TikTok, or third parties, then Amazon or TikTok may, in their sole discretion, withhold any payments owed for as long as they determine any related risk to persist. Further, if Amazon or TikTok determines that any seller’s accounts, including ours, have been used to engage in deceptive, fraudulent, or illegal activity, or that such accounts have repeatedly violated their policies, then Amazon or TikTok may, in their sole discretion, permanently withhold any payments owed. In addition, Amazon or TikTok, in their sole discretion, may suspend a seller account and product listings if they determine that a seller has engaged in conduct that violates any of their policies. Any limitation or restriction on our ability to sell on Amazon’s and TikTok’s platforms could have a material impact on our business, results of operations, financial condition, and prospects. We also rely on services provided by Amazon’s and TikTok’s fulfillment platforms, which provide for expedited shipping to the consumer — an important aspect in the buying decision for consumers. Any inability to market our products for sale with delivery and any failure to remain compliant with the fulfillment practices on Amazon’s and TikTok’s platforms could have a material impact on our business, results of operations, financial condition, and prospects.

Increases in ingredient costs, long lead times, supply shortages, and changes could disrupt our supply chain and negatively impact our business, financial condition, and operating results.

Our ability to meet customer demand relies on timely delivery of ingredients, many of which are sourced from a few contract manufacturers, some exclusively. These suppliers may breach agreements or face issues like market fluctuations, litigation, regulatory problems, or force majeure events, affecting their delivery capabilities.

The herbal supplement industry frequently faces litigation, potentially disrupting our suppliers’ ability to deliver ingredients. We risk ingredient shortages, long lead times, and supply modifications. Developing alternative sources can be time-consuming and costly, and may not always be successful.

Any interruption in supply or inability to secure ingredients at acceptable prices could prevent us from meeting product delivery schedules, harm our margins, and materially and adversely impact our future revenue and earnings.

We may allocate our limited resources to pursue particular products or services and may fail to capitalize on products or services that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we must focus our efforts on particular products and services. As a result, we may forego or delay pursuit of opportunities with other products or services that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Any such failure could result in missed opportunities and/or our focus on products or services with low market potential, which would materially and adversely affect our business, results of operations, and financial condition.

We may be subject to inventory spoliation.

Certain of our products are subject to definitive shelf-lives and may not be sold within such shelf-lives and/or may become spoiled. As a result, we may need to write-off inventory and may face significant charges for obsolete and spoiled inventory, which could have a material adverse effect on our business, results of operations, and financial condition.

Table of Contents

Failure to renew our current leases or locate desirable alternatives for our facilities could materially and adversely affect our business.

We lease properties for all of our offices and warehouses. We may not be able to successfully extend or renew such leases upon expiration of the current term on commercially reasonable terms or at all, and may therefore be forced to relocate the affected operations. This could disrupt our operations and result in significant relocation expenses, which could materially and adversely affect our business, results of operations, and financial condition. In addition, we compete with other businesses for premises at certain locations or of desirable sizes. As a result, even though we could extend or renew our leases, rental payments may significantly increase as a result of the high demand for the leased properties. In addition, we may not be able to locate desirable alternative sites for our facilities as our business continues to grow and failure in relocating our affected operations could materially and adversely affect our business and operations.

In the future, we may need licenses for third-party technology that could be unavailable or only offered on commercially unreasonable terms, potentially increasing our costs or causing unforeseen adverse effects.

Occasionally, we may need to license technologies or trademarks for our promotional and collaborative programs to further develop or commercialize our products. If required to obtain such licenses, including patents necessary for manufacturing, using, or selling our products, these licenses may not be available on reasonable terms or at all. Failure to obtain necessary third-party licenses could force us to abandon related efforts, which could materially and adversely affect our business, results of operations, and financial condition.

Due to the high costs and uncertainty of litigation, we may not be able to enforce our intellectual property rights against third parties.

Even if we identify third-party infringement, the risk-adjusted cost of litigation may be too high, making it impractical to pursue legal action. Competitors with greater financial resources and more developed intellectual property portfolios may better withstand the costs of complex patent litigation. The uncertainties of litigation could also hinder our ability to fund internal research, license necessary technology, or form development partnerships. As a result, we may choose to monitor the situation or seek non-litigious solutions instead of pursuing costly legal action. This approach could be more prudent and in the best interest of our Company and stockholders, although it could materially and adversely affect our business, results of operations, and financial condition.

We may struggle to partner with others for technological advancements and new products and services.

Our competitiveness partly relies on partnering with others who can offer technological improvements and enhance our existing products and services. We strive to stay current with changes in the herbal supplement industry and seek partners to develop new offerings for our customers. However, we cannot guarantee success in finding such partners or incorporating new technologies and developments. Additionally, there is no certainty that newly developed products and services will perform well or gain market acceptance, and the costs associated with these efforts may be substantial.

Our use of “open source” software could subject our proprietary software to general release, hinder our product sales, and expose us to potential litigation.

Some of our proprietary software includes “open source” software, and we may incorporate more open-source software in the future. Open-source software is typically licensed under terms that might require us to disclose our modifications and license them to third parties at no cost. In some cases, distributing our software alongside open-source software could compel us to release some or all of our proprietary code and distribute our products for free.

We monitor our use of open-source software to prevent such disclosures or licensing obligations, but we cannot guarantee success. Open-source license terms can be ambiguous, and inadvertent misuse may occur. Legal precedents on interpreting these licenses are limited, potentially leading to unanticipated obligations.

Companies using open-source software have faced claims enforcing open-source licenses and asserting ownership of incorporated software. If an open-source author or distributor alleges non-compliance, we could incur significant legal costs defending ourselves. Successful claims could result in substantial damages or an injunction against distributing our products.

Table of Contents

Additionally, combining our proprietary software with open-source software under certain licenses may force us to release our proprietary source code. This could aid competitors in developing similar or superior products, materially and adversely affecting our business, results of operations, and financial condition.

Our business is exposed to risks associated with credit card and other online payment chargebacks and fraud.

A majority of our revenue is processed through credit cards and other online payments. If we experience refunds or chargebacks, our processors could require us to create reserves, increase fees, or terminate contracts with us, which would have an adverse effect on our financial condition. Our failure to limit fraudulent transactions conducted on our websites, such as through the use of stolen credit card numbers, could also subject us to liability and adversely impact our reputation. Under credit card association rules, penalties may be imposed at the discretion of the association for inadequate fraud protection. Any such potential penalties would be imposed on our credit card processor by the association. However, we face the risk that we may fail to maintain an adequate level of fraud protection and that one or more credit card associations or other processors may, at any time, assess penalties against us or terminate our ability to accept credit card payments or other form of online payments from customers, which would have a material adverse effect on our business, financial condition, and results of operations.

We could also incur significant fines or lose our ability to give customers the option of using credit cards to pay for our products if we fail to follow payment card industry data security standards, even if there is no compromise of customer information. Although we believe we operate in compliance with payment card industry data security standards, it is possible that at times we may not be in full compliance with these standards. Accordingly, we could be fined, which could impact our financial condition, or our ability to accept credit and debit cards as payment could be suspended, which would cause us to be unable to process payments using credit cards. If we are unable to accept credit card payments, our business, results of operations, and financial condition may be materially and adversely affected.

In addition, we could be liable if there is a breach of the payment information. Online commerce and communications depend on the secure transmission of confidential information over public networks. We will rely on encryption and authentication technology to authenticate and secure the transmission of confidential information, including cardholder information. However, this technology may not prevent breaches of the systems we use to protect cardholder information. In addition, some of our contracting parties may also collect or possess information about our customers, and we may be subject to litigation or our reputation may be harmed if our contracting parties fail to protect our customers’ information or if they use it in a manner inconsistent with our policies and practices. Data breaches can also occur as a result of non-technical issues. Under contracts with processors, if there is unauthorized access to, or disclosure of, credit card information we store, we could be liable to the credit card issuing banks for their cost of issuing new cards and related expenses, which could have a material and adverse effect on our business, financial condition, and results of operations.

We face risks associated with our return policy and warranty.

We offer a seven-day return policy and a limited warranty on our products. Our return and warranty allowances are currently based on our best estimates of expected product returns, drawing on historical experience, which has been immaterial to date. However, there are risks associated with this policy that could impact our financial results if actual returns or warranty claims exceed our estimates:

• Unexpected Increase in Returns: Changes in consumer behavior, product quality issues, or shifts in consumer expectations could lead to a higher volume of returns than anticipated. An increase in product returns could directly impact our revenue and profitability.

• Warranty Claims Exceeding Expectations: While we have historically experienced minimal warranty claims, unexpected product defects or customer dissatisfaction could result in an increase in warranty claims. This would raise our costs for replacement or repair and impact our bottom line.

• Impact on Cash Flow and Inventory Management: Higher-than-expected returns or warranty claims could also impact our cash flow, inventory levels, and resource allocation. If our allowances are insufficient, we may need to adjust our reserves, affecting our reported financial results and cash position.

Table of Contents

While we use historical data to estimate returns and warranty allowances, there is a risk that these estimates may not accurately reflect future return or warranty claim rates. Any significant deviation from these estimates could result in unexpected costs and adjustments to our financial statements, and potentially affect investor confidence.

In sum, if our actual experience with returns and warranty claims differs materially from our estimates, our business, financial condition, and results of operations could be materially and adversely affected. We continuously monitor return and warranty trends to minimize these risks, but there can be no assurance that our allowances will be sufficient to cover future return or warranty-related expenses.

Our use of clinical studies presents inherent risks, particularly as our clinical study results have not demonstrated statistical significance.

Our products often rely on clinical studies to support efficacy claims, differentiate from competitors, and meet regulatory standards. However, clinical studies present inherent risks:

• Uncertain Outcomes: Clinical studies may yield results that do not support product efficacy claims, impacting our ability to market products effectively. Our clinical studies have not demonstrated statistically significant outcomes, which may diminish consumer confidence in our products and reduce demand.

• Regulatory Scrutiny: Clinical studies must comply with strict regulatory standards. Any failure to meet these standards or challenges in replicating results could hinder our ability to use these studies for marketing or compliance purposes, limiting our competitive advantage and appeal to consumers.

• Time and Cost Implications: Clinical studies are resource-intensive and time-consuming, requiring significant financial investment. Delays in completing studies or the need for additional studies due to inconclusive results could lead to increased costs and delays in product launches, which would negatively impact our financial condition and growth prospects.

• Consumer Perception of Study Integrity: The quality and transparency of clinical studies play a crucial role in consumer trust. If consumers perceive our studies as biased or of low quality, it could damage our brand reputation, reduce consumer demand, and impact our financial performance.

Thus, clinical studies carry risks that could adversely affect our business if they fail to meet regulatory standards, yield unfavorable results, or are perceived negatively by consumers. These factors, combined with economic and consumer trends, present material risks that could materially and adversely affect our business, financial condition, and results of operations.

Our business depends on our brands, and any failure to maintain, protect, or enhance our brands, including as a result of events outside our control, could materially and adversely affect our business, financial condition, and results of operations.

We believe our future success depends on our ability to maintain and grow the value of our brands, Dr. Herbal Well and Best Doctor Formula. Maintaining, promoting, and positioning our brands and reputation will depend on, among other factors, the success of our marketing and merchandising efforts and our ability to provide a consistent, high-quality customer experience. Any negative publicity, regardless of its accuracy, could materially and adversely affect our business. Brand value is based in large part on perceptions of subjective qualities, and any incident that erodes the loyalty of our customers, including adverse publicity or a governmental investigation or litigation, could significantly reduce the value of our brands and materially and adversely affect our business, financial condition, and results of operations.

The value of our brands also depends on effective customer support to provide a high-quality customer experience, which requires significant personnel expense. If not managed properly, this expense could impact our profitability. Failure to manage or train our own or outsourced customer support representatives properly, or our inability to hire sufficient customer support representatives could result in lower-quality customer support and/or increased customer response times, compromising our ability to handle customer complaints effectively.

Table of Contents

We source ingredients for our products from foreign suppliers and face risks related to international trade and importation.

We source ingredients for our products from international suppliers, primarily located in China. Relying on foreign suppliers for our raw materials exposes us to several risks associated with international trade and importation, including but not limited to the following:

• Shipment Delays and Disruptions: Transportation and logistical issues, such as shipping container shortages, port congestion, customs clearance delays, and disruptions in global supply chains, can lead to delayed or incomplete shipments of ingredients, which could affect our ability to meet production schedules and fulfill customer orders on time.

• Economic and Political Instability: Foreign markets are subject to political upheaval, changes in government policy, trade embargoes, and instability in local economies. These conditions could lead to restrictions on imports, increased duties or tariffs, and other trade barriers that may increase our costs or prevent the delivery of key ingredients.

• Quality Assurance and Compliance Risks: Foreign suppliers may face challenges in maintaining consistent product quality or complying with international and local regulations, including FDA standards, Good Manufacturing Practices (GMP), and other legal requirements applicable to dietary supplements. Despite our efforts to audit and inspect suppliers’ facilities periodically, lapses in quality control or regulatory compliance can occur, potentially leading to product recalls, reputational harm, or regulatory penalties.

• Health Pandemics and Natural Disasters: Future events similar to the COVID-19 pandemic or natural disasters (for instance, earthquakes, floods, or hurricanes) can disrupt manufacturing, labor availability, or transportation routes, resulting in delays or shortfalls in supply.

• Tariffs and Trade Disputes: Trade disputes between the U.S. and countries from which we source raw materials (including China), have in the past and may in the future result in the imposition of tariffs or other restrictive measures that increase the costs of importing essential ingredients or finished products.

• Currency Fluctuations: Fluctuations in exchange rates between the U.S. dollar and foreign currencies have in the past and may in the future increase the cost of goods sourced from overseas suppliers, impacting our profitability.

A substantial portion of our sales relies on distributors and health professionals, over whom we have limited control. If these relationships deteriorate, or if these parties fail to sell our products, harm our reputation, or fail to comply with regulations, our business, financial condition, and results of operations could be materially and adversely affected.

Our sales model depends on health professionals and distributors to sell our products. Health professionals typically receive discounts or rebates as an incentive to recommend or distribute our products. While these discounts and rebates are designed to encourage sales, they may reduce our profit margins. Additionally, there is no guarantee that health professionals will recommend or prioritize our products over competitors’, even with these incentives, which could negatively impact our revenue and market share. Failure to grow this network could hinder revenue growth or result in decreasing revenue.

In the U.S., we rely on select strategic distributors and a third-party reseller for Amazon sales. We do not control their operational decisions, such as warehousing space allocation, inventory management, or fulfillment prioritization, which has led to order backlogs in the past. These backlogs can result in delayed shipments, lost sales opportunities, and harm to our reputation. Additionally, these third-party providers may change their terms, reduce their focus on our products, or prioritize competing products, further negatively impacting our sales. The loss of one or more of these providers or continued operational challenges could disrupt our revenue streams. Transitioning to alternative distribution arrangements or a direct sales model may involve significant costs and logistical challenges, which could materially and adversely affect our business, financial condition, and results of operations.

Table of Contents

Our business relies on network and mobile infrastructure and maintaining and scaling our technology. Interruptions, delays, or errors in our apps or websites, including security flaws, could limit capacity, reduce demand, delay processing, and result in customer loss.

We aim to attract and retain customers through our DirecTCM platform and websites, which require substantial network capacity and computing power. Operational failures, such as system overloads or unexpected growth, could necessitate significant costs to upgrade infrastructure. Issues like system failures, viruses, security breaches, or other disruptions could harm our service reliability and customer access.

We rely on third-party providers, such as Amazon Web Services, for data storage, email services, and internet access. If these providers fail to meet our needs or terminate agreements, our operations could be significantly disrupted, affecting customer satisfaction and revenue.

Natural disasters, power losses, cyberattacks, or other events could disrupt our apps and websites, causing data loss and operational delays. While we have disaster recovery plans, they may be inadequate, and our business interruption insurance may not cover all losses. Such events could materially and adversely affect our business, financial condition, and results of operations.

We rely upon independent third-party transportation providers for all of our product shipments and are subject to increased shipping costs as well as the potential inability of our third-party transportation providers to deliver on a timely basis.

We rely upon independent third-party transportation providers for all of our product shipments, including shipments from our warehouses to our customers. Our utilization of these third-party delivery services for shipments is subject to risks which may impact a shipping company’s ability to provide delivery services that adequately meet our shipping needs, including risks related to employee strikes, labor and capacity constraints, port security considerations, trade policy changes or restrictions, military conflicts, acts of terrorism, accidents, natural disasters and inclement weather. Any interruption in service provided by our shipping companies could cause temporary disruptions in our business, a loss of sales and profits, and other material adverse effects. In addition, we are subject to increased shipping costs when fuel prices increase, as we use expedited means of transportation such as air freight. If we change the shipping company we use, we could face logistical difficulties that could adversely affect deliveries, and we would incur costs and expend resources in connection with such change. Any of these eventualities could materially and adversely affect our business, financial condition, and results of operations.

Our insurance does not fully cover all of our operational risks, and changes in the cost of insurance or the availability of insurance could materially increase our insurance costs or result in a decrease in our insurance coverage.

We are self-insured for a portion of our potential liabilities. In certain instances, our insurance may not fully cover an insured loss, depending on the magnitude and nature of the claim. For example, our products are subject to risks for product liability claims due to inherent potential side effects. We may be unable to obtain or maintain product liability coverage. A product liability claim in excess of, or excluded from, our insurance coverage, which currently covers exposure to product liability claims, would have to be paid out of cash reserves and could have a material and adverse effect upon our business, financial condition, and results of operations. Product liability insurance is expensive even with large self-insured retentions or deductibles, and difficult to maintain, and current or increased coverage may not continue to be available on acceptable terms, if at all. Additionally, changes in the cost of insurance or the availability of insurance in the future could substantially increase our costs to maintain our current level of coverage or could cause us to reduce our insurance coverage and increase the portion of our risks that we self-insure.

Disruptions in our data and information systems could harm our reputation and our ability to run our business.

We will rely extensively on data and information systems for our supply chain, financial reporting, human resources, and various other operations, processes, and transactions. Furthermore, a significant portion of the communications between us, our suppliers, and our customers depend on information technology. Our data and information systems are subject to damage or interruption from power outages, computer and telecommunications failures, computer viruses, security breaches (including breaches of our transaction processing or other systems that could result in the compromise of confidential customer data), catastrophic events, data breaches, and usage errors by

Table of Contents

our employees or third-party service providers. Our data and information technology systems may also fail to perform as we anticipate, and we may encounter difficulties in adapting these systems to changing technologies or expanding them to meet the future needs of our business. If our systems are breached, are damaged, or cease to function properly, we may have to make significant investments to fix or replace them, suffer interruptions in our operations, incur liability to our customers and others, or face costly litigation, and our reputation with our customers may be harmed. We also rely on third parties for a majority of our data and information systems, including for third-party hosting and payment processing. If these facilities fail, or if they suffer a security breach or interruption or degradation of service, a significant amount of our data could be lost or compromised and our ability to operate our business and deliver our product offerings could be materially impaired. In addition, various third parties, such as our suppliers and payment processors, also rely heavily on information technology systems, and any failure of these systems could also cause loss of sales, transactional, or other data and significant interruptions to our business. Any material interruption in the data and information technology systems we rely on, including the data or information technology systems of third parties, could materially and adversely affect our business, financial condition, and results of operations.

Failure to protect our intellectual property rights could adversely affect our business.

We regard our trademarks, domain names, trade secrets, proprietary technologies, and other intellectual property as critical to our success. See “Business — Intellectual Property.” We have taken measures to protect our intellectual property, but these measures might not be sufficient or effective. We may bring lawsuits to protect against the potential infringement of our intellectual property rights. Policing unauthorized use of our proprietary technology and other intellectual property is difficult and expensive, and litigation may be necessary in the future to enforce their intellectual property rights. Future litigation could result in substantial costs and diversion of our resources and could disrupt our business, as well as materially and adversely affect our financial condition and results of operations. Further, despite the potentially substantial costs, we cannot assure you that we will prevail in such litigation. In addition, our trade secrets may be leaked or otherwise become available to, or be independently discovered by, our competitors. Any failure in protecting or enforcing our intellectual property rights could have a material and adverse effect on our business, financial condition, and results of operations.

Third parties may claim that we infringe their proprietary intellectual property rights, which could cause us to incur significant legal expenses and prevent us from promoting our products.

We cannot be certain that our operations or any aspects of our business do not or will not infringe upon or otherwise violate trademarks, copyrights, or other intellectual property rights held by third parties. We may from time to time in the future be subject to legal proceedings and claims relating to the intellectual property rights of others. See “Business — Intellectual Property.” There could also be existing intellectual property of which we are not aware that our products may inadvertently infringe. If any third-party infringement claims are brought against us, we may be forced to divert management’s time and other resources from our business and operations to defend against these claims, regardless of their merits. Additionally, the application and interpretation of intellectual property right laws and the procedures and standards for granting trademarks, copyrights, or other intellectual property rights are evolving and may be uncertain, and we cannot assure you that courts or regulatory authorities would agree with our analysis. Such claims, even if they do not result in liability, may harm our reputation. If we were found to have violated the intellectual property rights of others, we may be subject to liability for our infringement activities or may be prohibited from using such intellectual property, and we may incur licensing fees or be forced to develop alternatives of our own. As a result, our business, financial condition, and results of operations may be materially and adversely affected.

If we cannot protect the confidentiality of our trade secrets and know-how, our business and competitive position may suffer.

Our ability to compete depends on maintaining the proprietary nature of our products, manufacturing processes, and services. We rely on trade secrets, know-how, license agreements, and contractual provisions to protect our intellectual property. If these protections fail, our intellectual property rights could be narrowed, terminated, or invalidated, severely impacting our sales and revenue.

We rely on unpatented trade secrets and know-how, which can be difficult to protect. We routinely use confidentiality agreements with vendors, employees, consultants, and others with access to proprietary information. However, unauthorized disclosure or use of this information can still occur despite these agreements. Monitoring such breaches is challenging, and we may not always have adequate remedies if they occur. Public disclosure by employees or other parties could result in the loss of trade secrets, enabling competitors to duplicate or surpass our technologies.

Table of Contents

We also use physical and technological security measures to protect our proprietary information, but these may not always be effective. Misappropriation by employees, collaborators, contractors, or other third parties remains a risk. Sharing proprietary information with partners in countries with heightened risks of theft can further endanger our trade secrets.

If our trade secrets are disclosed or misappropriated, our competitive position would be harmed, and the value of this information reduced. Additionally, trade secret protection varies by jurisdiction, and courts outside the U.S. may offer less protection. Trade secrets can be independently developed by others, preventing legal recourse by us. Any of the foregoing could have a material and adverse effect on our business, financial condition, and results of operations.

If our trademarks and trade names are not adequately protected, we may struggle to build name recognition, adversely affecting our business.

We rely on trademarks and trade names to promote our brand and products. Our trademarks may face challenges, opposition, or infringement, or be deemed generic, descriptive, or infringing on other marks. If we cannot protect these trademarks, we may have to stop using them, hindering our name recognition and market presence. Trademark applications may be rejected by the United States Patent and Trademark Office or foreign jurisdictions, and even if we can respond, we may not overcome such rejections. Third parties can oppose pending applications or seek to cancel registered trademarks, which may not survive such proceedings.

Inadequate name recognition could hinder our competitiveness and business. Licensing our trademarks to third parties, such as distributors, poses additional risks. Breaches or misuse by licensees could jeopardize our rights and diminish our trademarks’ goodwill. Enforcing or protecting our trademark rights can be costly, resource-intensive, and potentially ineffective, negatively impacting our business, financial condition, and results of operations.

Trademark litigation is expensive and uncertain. In many countries, a registered trademark may not suffice against a senior trademark infringement claim. Competitors or third parties may adopt similar trade names or trademarks, causing brand confusion and impeding our brand identity. Additionally, we may face infringement claims from other trademark owners. If we assert trademark claims, courts may rule our marks invalid, unenforceable, or that the other party has superior rights, forcing us to cease using those trademarks.

Our business is subject to risks from natural and manmade catastrophic events such as hurricanes, earthquakes, fires, power outages, floods, and terrorism.

Our operations are vulnerable to disruption from natural disasters like hurricanes, earthquakes, fires, floods, and power outages, as well as manmade events such as terrorism, war, human error, and break-ins. These risks also apply to the third-party systems, operations, and manufacturers we depend on. For instance, a major natural disaster, like an earthquake affecting our California locations, could materially and adversely affect our business, financial condition, and results of operations. Our insurance coverage may not fully compensate us for all losses.

Terrorist attacks, especially in densely populated metropolitan areas like Los Angeles, where our headquarters is located, could disrupt our business and the broader economy. We may lack adequate protection or recovery plans for certain scenarios, such as natural disasters affecting key inventory storage sites, our servers, or content generation locations. Our business relies heavily on computer and communication systems and the internet, so disruptions could significantly impact our operations and those of our suppliers and manufacturers, materially and adversely affecting our business, financial condition, and results of operations.

We recently experienced changes to our board of directors and management. These changes may create uncertainty and, more generally, if we are unable to attract or retain our key personnel, including our executive officers, senior management, and key employees, our ongoing operations and growth could be materially and adversely affected.

We recently experienced changes in our board of directors and management, as our former Chief Executive Officer and Director, Mr. Jackson Kwok, resigned on December 28, 2025, and the board of directors appointed Mr. Simon Cheng as the interim Chief Executive Officer and a Director on December 29, 2025. We are currently seeking a permanent Chief Executive Officer. The search for a permanent Chief Executive Officer may be time-consuming and expensive. We cannot ensure that we will be able to identify and hire a qualified candidate on a timely basis or at all, particularly in the highly competitive market for executive talent. This management transition may create uncertainty regarding our strategic direction, business operations, and corporate culture. Changes in our board and

Table of Contents

senior management and uncertainty regarding pending changes may disrupt our business and investor relationships and impair our ability to recruit and retain other needed personnel. Any such disruption or impairment could have an adverse effect on our business.

Our success depends, to a large extent, on the efforts of our key personnel, including our executive officers, senior management, and other key employees who have valuable experience, knowledge, and connections in the herbal supplement industry. There is no assurance that these key personnel will not voluntarily terminate their employment with us. We do not carry, and do not intend to procure, key person insurance on any of our senior management team. The loss of any of our key personnel could be detrimental to our ongoing operations. Our success will also depend on our ability to attract and retain qualified personnel to manage our existing operations as well as our future growth. We may not be able to successfully attract, recruit, or retain key personnel, and this could materially and adversely affect our business, financial condition, and results of operations.

Cybersecurity risks could adversely affect our business and disrupt our operations.

We rely on information technology systems to manage financial records, sensitive business information, and personal data about our employees, customers, and other third parties. These systems support our R&D, manufacturing operations, quality control, customer communications, order fulfillment, corporate records, and other critical functions. While we implement measures to protect this information, including multi-layer firewalls, intrusion detection systems, content filtering, endpoint security, centralized logging and alerting, email security mechanisms, and access control mechanisms, cybersecurity threats are increasingly sophisticated and diverse. We also seek independent third-party assessments and industry-standard certifications like PCI DSS Compliance to validate our security and compliance capabilities. “PCI DSS Compliance” refers to adhering to the Payment Card Industry Data Security Standard (“PCI DSS”), which is a set of security standards designed to protect cardholder data and help ensure the safe processing of credit card transactions. PCI DSS was created by major credit card brands (Visa, MasterCard, American Express, Discover, and JCB) to establish a unified set of security measures for organizations that handle cardholder information. To date, we have not experienced any data breaches or significant security incidents affecting our IT systems or the sensitive information we manage.

Despite our preventive efforts, our products, services, servers, and computer systems, as well as those of our third-party service providers, remain vulnerable to cybersecurity risks. These include cyberattacks such as viruses, worms, phishing, social engineering, denial-of-service, ransomware, physical or electronic break-ins, and theft or misuse by employees or third parties. Such attacks could lead to interruptions, data loss or corruption, unauthorized access to personal and health-related information, and loss of customer confidence. Additionally, we may be targeted by email scams and other attacks seeking personal information or access to our systems. Our third-party service providers face similar risks.

Any cyberattack, security breach, or incident affecting our systems or those of our third-party providers could materially and adversely affect our business, financial condition, and results of operations. These incidents can be costly to remedy, damage our reputation, and lead to negative publicity, which could impact demand for our products and services. We may also incur significant costs investigating and responding to such incidents and complying with legal obligations resulting from security breaches.

Cyber-attacks and security vulnerabilities could result in serious harm to our reputation, business, and financial condition.

Threats to network and data security are constantly evolving and becoming increasingly diverse and sophisticated. Our products and services, as well as our servers and computer systems and those of third parties that we rely on, are subject to cybersecurity risks inherent to companies that process personal data. An increasing number of organizations have disclosed breaches of their information security systems, some of which have involved sophisticated and highly targeted attacks.

We were recently informed, in July 2025, by our underwriter that it had suffered a cybersecurity incident and specifically a ransomware incident, which has resulted in unauthorized access to some of the underwriter’s systems and data, and the exfiltration of certain data from the underwriter’s systems as well. Based on information currently available to the underwriter regarding the incident, the underwriter believes that confidential information regarding the Company that we had provided to the underwriter in connection with its due diligence for this offering was included in the data that was exfiltrated. The underwriter is still investigating the extent of this incident and has also informed us that it does not have any evidence that this data has been publicly posted or otherwise misused by the threat actors at this time. The incident has not impacted our business operations and we do not expect the incident to impact our business operations in the future, as it did not involve unauthorized access to our systems or third-party systems that

Table of Contents

we use in our business operations. While we believe that any material data regarding the Company that was exfiltrated is reflected in this prospectus and the registration statement of which this prospectus is a part, and therefore is publicly available, we could be subject to liability risks to the extent the data consists of sensitive information about our officers, directors, personnel, contractors, customers, suppliers, or vendors. We believe that any such risk is manageable and can be absorbed and addressed by our existing cybersecurity policies, procedures, and controls.

To that end, we employ robust security to defend against intrusion and attack of our systems, to protect our data, and to resolve and mitigate the impact of any incidents. We also regularly educate our employees on these risks, and provide training to them to learn how to identify and respond to the same. Like most companies today, despite these efforts there is no way to fully remove the possibility of a cybersecurity incident from occurring and we, and third parties that we rely on, will likely experience cyber incidents in the future. Thus, in addition to the identified risk above, any additional future cyber incidents and resulting data breaches could result in substantial liability, regulatory actions, financial penalties, significant out of pocket costs, damage to our data and ability to do business, and reputational harm.

We and third parties that we rely on may experience cybersecurity incidents due to human error, malfeasance, system errors or vulnerabilities, or other issues. Actual or perceived cybersecurity incidents relating to our data or confidential information could subject us to regulatory investigations and orders, litigation, indemnity obligations, damages, penalties, fines and other costs in connection with actual and alleged contractual breaches, violations of applicable laws and regulations, and other liabilities. Any such incident could also materially damage our reputation and harm our business, results of operations, and financial condition. We maintain errors, omissions, and cyber liability insurance policies covering certain security and privacy damages. However, we cannot be certain that our coverage will always be adequate for the liabilities actually incurred or that insurance will continue to be available to us on economically reasonable terms, or at all, especially depending on the facts of the situation and method of incident.

We rely heavily on third parties for our computing, storage, processing, and related services. Any disruption or interference with these third-party services could negatively impact our business, financial condition, and results of operations.

Our cloud infrastructure is outsourced to third-party providers, which host and stream our customer-facing services and content. Consequently, we are vulnerable to service interruptions experienced by these providers. We may encounter interruptions, delays, or outages in service availability due to infrastructure changes, human error, hardware or software failures, hosting disruptions, and capacity constraints. Outages could result from technical failures, natural disasters, fraud, or security attacks. Any service level issues or prolonged interruptions could negatively impact our products and services, harm customer satisfaction, and damage our business and reputation.

As our customer base grows, hosting costs will increase. If we cannot grow our revenue faster than these costs, it could adversely affect our business. Additionally, our providers have broad discretion to change and interpret their terms of service and policies, which may not always be favorable to us. They could take actions beyond our control, such as discontinuing or limiting our access to services, increasing prices, terminating our contracts, or altering data analysis methods in ways that are unfavorable or costly to us.

While we could potentially obtain similar services from other third parties, transitioning would likely result in service interruptions, delays, and additional expenses. Any of these factors could reduce our revenue, subject us to liability, and cause customer loss, any of which could materially and adversely affect our business, financial condition, and results of operations.

Future acquisitions may have an adverse effect on our ability to manage our business. Raising additional capital may cause dilution to our stockholders, including purchasers of our common stock in this offering.

We may acquire businesses, technologies, services, or products that are complementary to our herbal supplement business. Future acquisitions may expose us to potential risks, including risks associated with the integration of new operations, services, and personnel, unforeseen or hidden liabilities, the diversion of resources from our existing business and technology, our potential inability to generate sufficient revenue to offset new costs, the expenses of acquisitions, or the potential loss of or harm to relationships with both employees and customers resulting from our integration of new businesses.

Any of the potential risks listed above could have a material and adverse effect on our business, financial condition, and results of operations. We may need to raise additional debt funding or sell additional equity securities to make such acquisitions. The raising of additional debt funding by our Company, if required, would result in increased

Table of Contents

debt service obligations and could result in additional operating and financing covenants, or liens on our assets, that would restrict our operations. The sale of additional equity securities could result in additional dilution to our stockholders.

Economic, Political, and Market Risks

We rely on third-party contract manufacturers located in China to produce our supplements, making us highly vulnerable to U.S. tariffs, trade disputes, and other disruptions related to U.S.-China trade relations, which could significantly increase our costs and materially harm our business.

We rely on contract manufacturers located in China for the production of all our supplement products. This complete reliance on manufacturing partners in a single country exposes us to significant risks associated with U.S.-China trade relations, particularly the imposition and potential modification of U.S. tariffs on goods imported from China.

In recent years, and particularly in 2025, the U.S. government has implemented substantial tariffs on a wide range of goods imported from China under various authorities. Current tariff levels on many Chinese goods, potentially including supplements or their raw ingredients/components, are significant, reaching levels that substantially increase the landed cost of our imported products. Furthermore, the U.S. administration has demonstrated a willingness to modify these tariffs, sometimes rapidly, creating significant uncertainty regarding our future import costs. Recent statements suggest potential future adjustments, but the timing, scope, and direction of any changes remain highly uncertain. While we do not export products to China, broader trade tensions or actions taken by China could still potentially impact global logistics or the availability of certain finished goods relevant to our supply chain.

These tariffs have had, and future tariffs or increases in existing tariffs could have, significant adverse effects on our business, including:

• Increased Costs and Reduced Margins: Tariffs directly increase our cost of goods sold, as we are generally responsible for paying the tariffs imposed on the finished supplements imported from our Chinese contract manufacturers. If we are unable to pass these increased costs onto our customers, negotiate offsetting price reductions from our manufacturers, or find alternative cost-effective manufacturing options, our gross margins and profitability will be materially and adversely affected;

• Need for Price Increases and Potential Impact on Demand: To offset higher tariff-related costs, we may need to increase the prices of our supplements. Such price increases could make our products less competitive, potentially leading to reduced customer demand, loss of market share, and lower revenue;

• Supply Chain Disruptions and Costs: The current trade environment could disrupt our supply chain. While we may seek alternative contract manufacturers outside of China to mitigate tariff risks, identifying, qualifying, and transitioning production of our specific supplement formulations to new manufacturers can be a complex, time-consuming, and costly process. Finding manufacturers with the necessary expertise, certifications (for instance, GMP), capacity, and cost-effectiveness for supplement production can be challenging. There is no guarantee we can find suitable alternative manufacturers on commercially acceptable terms, or at all. Delays in transitioning manufacturers or disruptions with our existing manufacturers due to trade tensions could negatively impact our ability to maintain inventory and meet customer demand;

• Competitive Disadvantage: If our competitors utilize manufacturers in other countries, are less reliant on suppliers in China, or are better able to mitigate the impact of tariffs, we could be placed at a competitive disadvantage; and

• Uncertainty and Planning Challenges: The ongoing uncertainty surrounding U.S.-China trade relations and tariff policies makes it difficult to forecast costs, plan inventory levels, manage our manufacturing relationships, and implement long-term business strategies, potentially hindering our growth and operational efficiency.

Any escalation in trade tensions, further increases in tariffs, imposition of quotas, or other restrictions could exacerbate these risks. The cumulative impact of these tariffs and the related uncertainty could materially and adversely affect our business, financial condition, results of operations, and future prospects.

Table of Contents

We face competition in the herbal supplement industry, and we expect competition from existing competitors and other companies that may enter the market or introduce new solutions in the future, which may decrease our net revenue.

The herbal supplement industry is highly competitive and subject to rapid change. The industry is expected to continue to expand and evolve as an increasing number of competitors and potential competitors enter the market. Many of these competitors and potential competitors have substantially greater financial, technological, managerial, and R&D resources and experience than we do. We plan to mainly compete with other companies offering herbal supplements, targeting health and wellness, including dietary supplements, functional foods, and natural remedies. These competitors and potential competitors may have more experience than we do. In addition, our planned services and products will compete with service and product offerings from large and well-established companies that have greater marketing and sales experience and capabilities than we or the parties with which we contract have. If we are unable to compete successfully, we may be unable to grow and sustain our revenue.

We believe that our ability to compete depends upon many factors both within and beyond our control, including:

• our marketing efforts;

• the flexibility and variety of our product offerings relative to our competitors, and our ability to timely launch new product initiatives;

• the quality and price of products offered by us and our competitors;

• our reputation and brand strength relative to our competitors;

• customer satisfaction;

• the size and composition of our customer base;

• our ability to comply with, and manage the costs of complying with, laws and regulations applicable to our business; and

• our ability to cost-effectively source and distribute the products we offer and to manage our operation.

Many competitors also have longer operating histories, and will have larger fulfillment infrastructures, greater technical capabilities, faster shipping times, lower-cost shipping, lower operating costs, greater financial, marketing, institutional, and other resources, and larger consumer bases than we do. These factors may also allow our competitors to derive greater revenue and profits from their existing consumer bases, acquire consumers at lower costs, or respond more quickly than we will be able to, to new or emerging technologies and changes in product trends and consumer shopping behavior. These competitors may engage in more extensive R&D efforts, enter or expand their presence in any or all of the ecommerce or retail channels where we plan to compete, undertake more far-reaching marketing campaigns, and adopt more aggressive pricing policies, which may allow them to build larger consumer bases or generate revenue from their existing consumer bases more effectively than we will be able to. As a result, these competitors may be able to offer comparable or substitute products to consumers at similar or lower costs. This could put pressure on us to lower our prices, resulting in lower revenue and margins or cause us to lose market share even if we lower prices.

Furthermore, companies with greater resources or more well-known brand names may attempt to compete with us, and as a result, we may lose current or potential customers and may be unable to generate sufficient revenue to support our operations, any one of which could have a material adverse effect on our ability to grow and our results of operations.

We may lose customers if we fail to compete successfully, which could adversely affect our financial performance and business prospects. We cannot guarantee that our strategies will remain competitive or successful in the future. Increasing competition may result in pricing pressure and loss of our market share, either of which could have a material adverse effect on our business, financial condition, and results of operations.

Table of Contents

Global economic conditions could materially and adversely affect the Company’s business, financial condition, results of operations, and growth.

Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs, changes to fiscal and monetary policy, tighter credit, higher interest rates, high unemployment, and currency fluctuations could materially and adversely affect the Company operations, expenses, access to capital, and the market for the Company’s products. In addition, consumer confidence and spending could be adversely affected in response to financial market volatility, negative financial news, conditions in the real estate and mortgage markets, declines in income or asset values, changes to fuel and other energy costs, labor and healthcare costs, and other economic factors.

In addition, uncertainty about, or a decline in, global or regional economic conditions could have a significant impact on the Company’s expected funding sources, suppliers, and partners. Potential effects include financial instability, inability to obtain credit to finance operations and purchases of the Company’s products, and insolvency.

A downturn in the economic environment could also lead to limitations on the Company’s ability to issue new debt, reduced liquidity, and declines in the fair value of the Company’s financial instruments. These and other economic factors could materially and adversely affect the Company’s business, financial condition, results of operations, and growth.

We operate in an industry with the risk of intellectual property litigation. Claims of infringement against us may hurt our business.

We must protect the proprietary nature of the intellectual property used in our business. There can be no assurance that trade secrets and other intellectual property will not be challenged, invalidated, misappropriated, or circumvented by third parties.

Additionally, our success depends, in part, upon non-infringement of intellectual property rights owned by others and being able to resolve claims of intellectual property infringement without major financial expenditures or adverse consequences. Participants that own, or claim to own, intellectual property may aggressively assert their rights. From time to time, we may be subject to legal proceedings and claims relating to the intellectual property rights of others. Future litigation may be necessary to defend us by determining the scope, enforceability, and validity of third-party proprietary rights or to establish its proprietary rights. Our competitors have substantially greater resources and are able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. Regardless of whether claims that we are infringing patents or other intellectual property rights have any merit, these claims are time-consuming and costly to evaluate and defend and could:

• cause delays or stoppages in providing products;

• divert management’s attention and resources;

• require technology changes to our products that would cause our Company to incur substantial cost;

• subject us to significant liabilities; or

• require us to cease some or all of our activities.

In addition to liability for monetary damages, which may be tripled and may include attorneys’ fees, or, in some circumstances, damages against clients, we may be prohibited from developing, commercializing, or continuing to provide some or all of our products unless we obtain licenses from, and pay royalties to, the holders of the patents or other intellectual property rights, which may not be available on commercially favorable terms, or at all. Any of the foregoing may have a material and adverse effect on our business, financial condition, and results of operations.

Legal, Regulatory, and Compliance Risks

We are subject to numerous laws and regulations applicable to the herbal supplement industry, which, if we are found to have violated, may materially and adversely affect our business, financial condition, and results of operations.

Our operations are regulated by U.S. federal agencies such as the FDA, as well as various state agencies. These regulations cover product design, development, labeling, manufacturing, handling, sales, and distribution. Failure to comply with these regulations may lead to fines, product recalls, or halting production, increasing costs, and reducing sales.

Table of Contents

For instance, the FDA may regulate medical or health-related software if classified as a “medical device” under the FFDCA. Currently, we believe our software products are not subject to active FDA regulation, but this could change with new FDA guidance or interpretations. If our products are deemed medical devices, we would need to comply with applicable FDA requirements, potentially including premarket and post-market obligations, which could be costly or difficult, and which could force us to cease using our DirecTCM platform.

The FDA could inspect one of our facilities or those of one of our contract manufacturers and determine that the facility was not in compliance with these regulations, and cause affected products made or held in the facility to be subject to FDA enforcement actions.

We are also required to adhere to laws governing the handling, transportation, manufacture, use, and sale of toxic or hazardous substances. Non-compliance could result in product recalls, market withdrawals, fines, or operational restrictions, any of which would increase costs and decrease sales.

Changes in FDA and other regulatory agency policies, or disagreements over our product classifications, could delay or increase the costs of offering our products, impacting our business.

Our business centers on the manufacturing and development of dietary supplements and health products, subjecting us to a complex landscape of regulatory requirements within the United States. These regulations encompass multiple categories, including dietary supplements, pharmaceuticals, medical devices, food products, and cosmetics. The FDA, along with other federal and state regulatory bodies, enforce policies that govern product safety, efficacy, labeling, manufacturing standards, and marketing practices.

Potential Impacts of Regulatory Changes — Changes in FDA regulations or shifts in policy by other regulatory agencies could directly impact our product classifications, labeling requirements, and manufacturing processes. Such changes may necessitate modifications to our products or business operations, potentially delaying our time to market, incurring additional compliance costs, or limiting our ability to distribute certain products. For example, if the FDA reclassifies certain ingredients commonly used in TCM or plant-based supplements, our formulations may require adjustments, which could be time-consuming and costly.

Risks Related to Product Classification Disputes — As we develop products that blend TCM and plant-based supplements, there is a risk of regulatory disputes regarding product classification. If a regulatory agency, such as the FDA, determines that one of our products should be classified as a drug rather than a dietary supplement, we would need to undertake a costly and lengthy approval process, including clinical trials and extensive testing. This process could delay our ability to offer the product or render it commercially unviable.

Compliance Challenges and Operational Risks — Our operations must comply with federal and state regulations that govern dietary supplements and related health products, including GMP, accurate labeling, and advertising standards. Failure to meet these requirements could lead to enforcement actions such as warning letters, fines, or even product recalls. These consequences could disrupt our supply chain, increase operational costs, damage our reputation, and limit our market reach.

Consequences of Non-Compliance — Non-compliance with applicable federal or state regulations may lead to severe repercussions, such as the issuance of warning letters, injunctions, mandatory recalls, or other enforcement actions. These penalties could halt our production, limit our sales, and significantly impact our financial condition and reputation in the marketplace. Additionally, repeat non-compliance could result in more severe penalties or potential legal action, which would further jeopardize our business operations and financial stability.

Any of the foregoing could have a material and adverse effect on our business, financial condition, and results of operations.

We and our suppliers must comply with numerous laws and regulations related to the manufacture, sale, and marketing of herbal supplements. Compliance with these laws can increase costs, limit our ability to sell certain products, and expose us to enforcement actions, any of which could materially and adversely affect our business, financial condition, and results of operations.

Our business is regulated by various agencies, including the FDA and FTC along with state and local authorities. These regulations cover manufacturing, packaging, labeling, distribution, advertising, quality, and safety. For example, the FDA’s DSHEA regulates dietary supplements, allowing structure and function claims but prohibiting disease-related claims.

Table of Contents

Our products must comply with cGMP, and our facilities are subject to unannounced inspections. Non-compliance can lead to sanctions, fines, recalls, and other penalties affecting our operations. The FDA has broad enforcement authority, including the ability to issue warnings, request recalls, and pursue legal action. The FSMA allows the FDA to refuse imports from non-compliant foreign suppliers. The FTC and state agencies also regulate advertising, and failure to comply can result in claims of false advertising and other legal issues.

We rely on suppliers to ensure compliance, seeking certifications and indemnifications. However, non-compliance can still harm our reputation and consumer confidence. Future regulations could increase our costs, require product reformulation, or result in recalls. These changes could materially and adversely affect our business, financial condition, and results of operations.

Our manufacturing processes, and those of our suppliers, involve the use of hazardous materials and chemicals, which produce waste products. Consequently, we and our suppliers are subject to federal, state, and local laws and regulations governing the use, manufacture, storage, handling, and disposal of hazardous materials and waste products. For example, the EPA regulates the generation and disposal of certain hazardous wastes. Additionally, laws like the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (“CERCLA”), and other state, local, or foreign regulations, may impose liabilities for the costs of remediating contaminated properties.

We may also face environmental, health, and safety claims and proceedings. While we believe we are in substantial compliance with applicable environmental regulations, any failure to fully comply could result in significant penalties, fines, and sanctions, potentially having a material adverse effect on our business, financial condition, and results of operations.

Our use and handling of personal information, including health data, is regulated by HIPAA and other privacy laws. Non-compliance could result in significant liability, harm our reputation, and materially and adversely affect our business.

We collect substantial personalized health information for our services, subject to various laws governing privacy and security. For example, HIPAA mandates strict standards for protecting PHI and requires us to maintain policies and safeguards. Violations can result in severe penalties and legal actions.

HIPAA requires prompt notification of any unauthorized access to PHI. If a breach affects 500 or more individuals, it must be reported to U.S. Department of Health and Human Services (“HHS”) and local media, with smaller breaches logged and reported annually. Beyond HIPAA, other federal, state, and international laws also regulate health data privacy, often more restrictively. These laws are complex and evolving, adding to our compliance burden.

This complex regulatory landscape requires us to implement robust privacy and security measures, but compliance challenges remain. Failures in compliance can lead to investigations, fines, and litigation, harming our business and reputation. Moreover, evolving privacy concerns can reduce customer trust and demand for our services, materially and adversely affecting our financial condition, and results of operations.

We may occasionally face legal proceedings, regulatory disputes, and governmental inquiries that could incur significant expenses, divert management’s attention, and harm our business, financial condition, and results of operations.

We may occasionally face legal proceedings, regulatory disputes, and governmental inquiries involving product liability, competition, antitrust, intellectual property, privacy, data protection, information security, customer protection, securities, tax, labor, employment, and commercial disputes. Such proceedings, especially those related to intellectual property infringement, can be lengthy, costly, and unpredictable. Some claims may seek substantial damages or injunctive relief, potentially leading to significant litigation costs.

Litigation outcomes are uncertain, and unfavorable results could lead to costly settlements, fines, or required changes to our products and services. Even if resolved in our favor, the time and resources spent on these matters could materially and adversely affect our business, financial condition, and results of operations.

Table of Contents

The applicability of sales, use, and other tax laws to our business is uncertain. Adverse tax laws or regulations could be enacted, or existing laws could be applied to us or our clients, leading to additional tax liabilities, penalties, increased costs, and a negative impact on our business.

Tax laws for e-commerce services are evolving, and new taxes could be introduced or existing laws changed, possibly retroactively. These changes could disproportionately affect online services and materially and adversely affect our business, financial condition, and results of operations.

State, local, and foreign tax jurisdictions have different and complex rules for sales, use, value-added, and other taxes. These rules can change and be interpreted in various ways over time. If new or existing tax laws are applied adversely to us, we could face significant tax liabilities for past sales, increased administrative burdens, and potential harm to our business, financial condition, and results of operations.

Our resellers are responsible for collecting and paying taxes on sales to end-users, while we handle taxes on direct sales. If it is determined that we have not properly collected and remitted taxes, we could face substantial liabilities, including interest and penalties, materially and adversely affecting our results of operations and cash balance.

Economic downturns or a change in consumer preferences, perception and spending habits could limit consumer demand for our products and negatively affect our future business.

The demand for the products we sell may be adversely affected from time to time by economic downturns that impact consumer spending, including discretionary spending. Future economic conditions such as employment levels, business conditions, housing starts, market volatility, interest rates, inflation rates, energy and fuel costs, and tax rates, or our actions in response to these conditions, such as price increases, could reduce consumer spending or change consumer purchasing habits.

Our performance depends significantly on factors that may affect the level and pattern of consumer spending in the markets in which we operate. Such factors include consumer preference, consumer confidence, consumer income, consumer perception of the safety and quality of our products, and shifts in the perceived value for our products relative to alternatives. A general decline in the consumption of our products could occur at any time as a result of change in consumer preference, perception, confidence, and spending habits, including an unwillingness to pay a premium or an inability to purchase our products due to financial hardship or increased price sensitivity, inflationary pressures, and economic uncertainty. If consumer preferences shift away from our products, our business, financial condition, and results of operations could be materially and adversely affected.

The success of our products depends on a number of factors including our ability to accurately anticipate changes in market demand and consumer preferences, our ability to differentiate the quality of our products from those of our competitors, and the effectiveness of our marketing and advertising campaigns for our products. We may not be successful in identifying trends in consumer preferences and developing products that respond to such trends in a timely manner. We also may not be able to effectively promote our products by our marketing and advertising campaigns and gain market acceptance. If our products fail to gain market acceptance, are restricted by regulatory requirements or have quality problems, we may not be able to fully recover costs and expenses incurred in our operations, and our business, financial condition, results of operations, and prospects could be materially and adversely affected.

Marketing activities for our products are subject to strict governmental regulation which may limit our ability to market or promote such products.

Our product advertising and promotion in the United States are regulated by the FTC under the FTC Act. The FTC Act mandates that advertisers have a “reasonable basis” for all product claims before making them and possess competent and reliable scientific evidence for health and therapeutic claims. Inadequate substantiation can render claims deceptive or misleading. The FTC Act also governs the appropriate use and required disclosures for promotional statements made by social media influencers and product testimonials.

The FTC has been active in investigating and taking action against companies that sell dietary supplements, providing guidance to help companies comply with its substantiation requirements. We believe we have sufficient substantiation for all material advertising claims for our products in the United States and have organized our documentation accordingly. However, we cannot guarantee that the FTC would agree if it were to review our claims.

Table of Contents

The DSHEA permits “statements of nutritional support” to be included in labeling for dietary supplements without premarket FDA approval. Such statements must be submitted to the FDA within 30 days of marketing and must bear a label disclosure that “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” Such statements may describe how a particular dietary ingredient affects the structure, function, or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect body structure, function, or well-being, but may not expressly or implicitly represent that a dietary supplement will diagnose, cure, mitigate, treat, or prevent a disease. A company that uses a statement of nutritional support in labeling must possess scientific evidence substantiating that the statement is truthful and not misleading. If the FDA were to determine that a particular statement of nutritional support was an unacceptable drug claim or an unauthorized version of a disease claim for a food product, or if the FDA were to determine that a particular claim was not adequately supported by existing scientific data or was false or misleading, we would be prevented from using that claim.

These restrictions may be more burdensome for our products, increase our expenses, reduce our ability to market our products, and ultimately have a negative effect on our results of operations. In the event we violate such rules and regulations we could face penalties, fines, and judgments, which could restrict our future operations and marketing.

Failure to comply with federal, state, and foreign laws and regulations relating to privacy, data protection, and consumer protection, or the expansion of current or the enactment of new laws or regulations relating to privacy, data protection, and consumer protection, could materially and adversely affect our business, financial condition, and results of operations.

A variety of federal, state, and foreign laws and regulations govern the collection, use, retention, sharing, and security of consumer data. Laws and regulations relating to privacy, data protection, and consumer protection are evolving and subject to potentially differing interpretations. These requirements may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another or may conflict with other rules or our practices. As a result, our practices may not comply with all such laws, regulations, requirements, and obligations. Any failure, or perceived failure, by us to comply with any federal, state, or foreign privacy or consumer protection-related laws, regulations, industry self-regulatory principles, industry standards or codes of conduct, regulatory guidance, orders to which we may be subject, or other legal obligations relating to privacy or consumer protection could adversely affect our reputation, brands, and business, and may result in claims, investigations, proceedings, or actions against us by governmental entities or others or other liabilities or require us to change our operations.

We will collect, store, process, and use personal information and other customer data, and rely on third parties that are not directly under our control to manage certain of these operations and to collect, store, process, and use payment information. Our customers’ personal information may include names, addresses, phone numbers, email addresses, payment card data, and payment account information, as well as other information. Due to the volume and sensitivity of the personal information and data we and these third parties will manage, the security features of our information systems are critical. If our security measures, some of which will be managed by third parties, are breached or fail, unauthorized persons may be able to access sensitive customer data, including payment card data. If we or our independent service providers or business partners experience a breach of systems that collect, store, or process our members’ and customers’ sensitive data, our brand could be harmed, sales of our products could decrease, and we could be exposed to claims, losses, administrative fines, litigation, or regulatory and governmental investigations and proceedings. Any such claim, investigation, proceeding, or action could hurt our reputation, brands, and business, force us to incur significant expenses in defense of such proceedings, distract our management, increase our costs of doing business, result in a loss of customers and suppliers, and may result in the imposition of monetary penalties and administrative fines. Depending on the nature of the information compromised, we may also have obligations to notify users, law enforcement, or payment companies about the incident and may need to provide some form of remedy, such as refunds, for the individuals affected by the incident.

Privacy laws, rules, and regulations are constantly evolving in the United States and abroad and may be inconsistent from one jurisdiction to another. We expect that new industry standards, laws, and regulations will continue to be proposed regarding privacy, data protection and information security in many jurisdictions, including the California Consumer Privacy Act of 2018, which went effective January 1, 2020, the California Consumer Privacy Rights Act, which went effective on January 1, 2023, and others. We cannot yet determine the impact such future laws, regulations, and standards may have on our business. Complying with these evolving obligations is costly. For instance, expanding definitions and interpretations of what constitutes “personal data” (or the equivalent) within the United States and

Table of Contents

elsewhere may increase our compliance costs. Any failure to comply could give rise to unwanted media attention and other negative publicity, damage our customer and consumer relationships and reputation, and result in lost sales, claims, administrative fines, lawsuits, or regulatory and governmental investigations and proceedings and may materially and adversely affect our business, financial condition, and results of operations.

We may be the subject of allegations, harassment, or other detrimental conduct by third parties, which could harm our reputation and cause us to lose market share and customers.

We may be subject to allegations by third parties or purported former employees, negative Internet postings, and other adverse public exposure on our business, operations, and staff compensation. We may also become the target of harassment or other detrimental conduct by third parties or disgruntled former or current employees. Such conduct may include complaints, anonymous or otherwise, to regulatory agencies, media, or other organizations. We may be subject to government or regulatory investigation or other proceedings as a result of such third-party conduct and may be required to spend significant time and incur substantial costs to address such third-party conduct, and there is no assurance that we will be able to conclusively refute each of the allegations within a reasonable period of time, or at all. Additionally, allegations, directly or indirectly against our Company, may be posted on the Internet, including social media platforms by anyone on an anonymous basis. Any negative publicity concerning our Company or our management can be quickly and widely disseminated. Social media platforms and devices immediately publish the content of their users’ posts, often without filters or checks on the accuracy of the content posted. The information posted may be inaccurate and adverse to our Company, and it may harm our reputation, business, or prospects. The harm may be immediate without affording us an opportunity for redress or correction. Our reputation may be negatively affected as a result of the public dissemination of negative and potentially false information about our business and operations, which in turn may cause us to lose market share and customers.

Common Stock and Trading Risks

There has been no public market for our common stock prior to this offering, and you may not be able to resell our common stock at or above the price you pay for them, or at all.

Prior to this offering, there has not been a public market for our common stock. We have applied for the listing of our common stock on Nasdaq. An active public market for our common stock, however, may not develop or be sustained after the offering, in which case the market price and liquidity of our common stock will be materially and adversely affected.

The market price of our common stock may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the initial public offering price.

The initial public offering price for our common stock will be determined through negotiations between the underwriters and us and may vary from the market price of our common stock following our initial public offering. If you purchase our common stock in our initial public offering, you may not be able to resell those shares at or above the initial public offering price. We cannot assure you that the initial public offering price of our common stock, or the market price following our initial public offering, will equal or exceed prices in privately negotiated transactions of our shares that have occurred from time to time prior to our initial public offering. The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:

• actual or anticipated fluctuations in our revenue and other operating results;

• the financial projections we may provide to the public, any changes in these projections, or our failure to meet these projections;

• actions of securities analysts who initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow our Company, or our failure to meet these estimates or the expectations of investors;

• announcements by us or our competitors of significant products or features, technical innovations, acquisitions, strategic partnerships, joint ventures, or capital commitments;

• price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole;

Table of Contents

• lawsuits threatened or filed against us; and

• other events or factors, including those resulting from war or incidents of terrorism, or responses to these events.

In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. Stock prices of many companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have filed securities class litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business, and adversely affect our business.

The price of our common stock could be subject to rapid and substantial volatility.

There have been instances of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with recent initial public offerings, especially among those with relatively smaller public floats. As a relatively small-capitalization company with a relatively small public float, we may experience greater stock price volatility, extreme price run-ups, lower trading volume, and less liquidity than large-capitalization companies. In particular, our common stock may be subject to rapid and substantial price volatility, low volumes of trades, and large spreads in bid and ask prices. Such volatility, including any stock run-ups, may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock.

In addition, if the trading volumes of our common stock are low, persons buying or selling in relatively small quantities may easily influence the price of our common stock. This low volume of trades could also cause the price of our common stock to fluctuate greatly, with large percentage changes in price occurring in any trading day session. Holders of our common stock may also not be able to readily liquidate their investment or may be forced to sell at depressed prices due to low volume trading. Broad market fluctuations and general economic and political conditions may also adversely affect the market price of our common stock. As a result of this volatility, investors may experience losses on their investment in our common stock. A decline in the market price of our common stock also could adversely affect our ability to issue additional shares of common stock or other of our securities and our ability to obtain additional financing in the future. No assurance can be given that an active market in our common stock will develop or be sustained. If an active market does not develop, holders of our common stock may be unable to readily sell the shares they hold or may not be able to sell their shares at all.

You will experience immediate and substantial dilution in the net tangible book value of common stock purchased in this offering.

The initial public offering price of our common stock is substantially higher than the net tangible book value per share of our common stock. Consequently, when you purchase shares of our common stock in the offering, upon completion of the offering you will incur immediate dilution of $3.75 per share, assuming an initial public offering price of $4.0 per share. See “Dilution.” In addition, you may experience further dilution to the extent that additional shares of common stock are issued upon exercise of outstanding options we may grant from time to time.

If we fail to implement and maintain an effective system of internal controls or fail to remediate the material weaknesses in our internal control over financial reporting that have been identified, we may fail to meet our reporting obligations or be unable to accurately report our results of operations or prevent fraud, and investor confidence and the market price of our common stock may be materially and adversely affected.

Prior to this offering, we have been a private company with limited accounting personnel and other resources with which to address our internal controls and procedures. Our independent registered public accounting firm has not conducted an audit of our internal control over financial reporting. However, in preparing our consolidated financial statements as of and for the three months ended December 31, 2025 and for the fiscal years ended September 30, 2025 and 2024, we have identified material weaknesses in our internal control over financial reporting and other control deficiencies. The material weaknesses identified included (i) a lack of formal policies and procedures to establish risk assessment process and internal control framework; and (ii) information technology-related deficiencies in the areas of: a) risk and vulnerability assessment, b) third-party (service organization) vendor management, c) backup management, disaster recovery, and proper equipment in physical environment control, and d) system security and access.

Table of Contents

Following the identification of the material weaknesses and control deficiencies, we have taken certain remedial measures, including adopting directors’ resolutions to appoint independent directors, establish an audit committee, and strengthen corporate governance. We plan to take additional remedial measures, including (i) hiring more qualified accounting personnel with relevant generally accepted accounting principles in the United States of America (“U.S. GAAP”) and SEC reporting experience and qualifications to strengthen the financial reporting function and to set up a financial and system control framework; and (ii) implementing regular and continuous U.S. GAAP accounting and financial reporting training programs for our accounting and financial reporting personnel.

However, the implementation of these measures may not fully address the material weaknesses in our internal control over financial reporting. Our failure to correct the material weaknesses or our failure to discover and address any other material weaknesses or control deficiencies could result in inaccuracies in our financial statements and could also impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. As a result, our business, financial condition, results of operations, and prospects, as well as the trading price of our common stock, may be materially and adversely affected. Moreover, ineffective internal control over financial reporting significantly hinders our ability to prevent fraud.

Upon completion of this offering, we will become a public company in the United States subject to the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act of 2002 will require that we include a report of management on our internal control over financial reporting in our annual report on 10-K beginning with our annual report for the fiscal year ending September 30, 2027. In addition, once we cease to be an “emerging growth company,” as such term is defined in the JOBS Act, our independent registered public accounting firm must attest to and report on the effectiveness of our internal control over financial reporting. Our management may conclude that our internal control over financial reporting is not effective. Moreover, even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm, after conducting its own independent testing, may issue a report that is qualified, if it is not satisfied with our internal controls or the level at which our controls are documented, designed, operated, or reviewed, or if it interprets the relevant requirements differently from us. In addition, after we become a public company, our reporting obligations may place a significant strain on our management, operational, and financial resources and systems for the foreseeable future. We may be unable to complete our evaluation testing and any required remediation in a timely manner.

We will incur substantial increased costs as a result of being a public company.

Upon consummation of this offering, we will incur significant legal, accounting, and other expenses as a public company that we did not incur as a private company. These additional costs could negatively affect our financial results. The Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the SEC and Nasdaq, impose various requirements on the corporate governance practices of public companies.

Compliance with these laws, rules, and regulations increases our legal and financial compliance costs and makes some corporate activities more time-consuming and costlier. These laws, regulations, and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations, and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. We have incurred additional costs in obtaining director and officer liability insurance. In addition, we incur additional costs associated with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors or as executive officers.

We are an “emerging growth company,” as defined in the JOBS Act and will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior March 31, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation requirement under Section 404 in the assessment of the emerging growth company’s internal control over financial reporting and permission to delay adopting new or revised accounting standards until such time as those standards apply to private companies.

Table of Contents

After we are no longer an “emerging growth company,” or until five years following the completion of our initial public offering, whichever is earlier, we expect to incur significant additional expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404 and the other rules and regulations of the SEC. For example, as a public company, we have been required to increase the number of independent directors and adopt policies regarding internal controls and disclosure controls and procedures.

We are currently evaluating and monitoring developments with respect to these rules and regulations, and we cannot predict or estimate with any degree of certainty the amount of additional costs we may incur or the timing of such costs.

If we cannot continue to satisfy the listing requirements and other rules of Nasdaq, our securities may be delisted, which could negatively impact the price of our securities and your ability to sell them.

We have applied to have our common stock listed on Nasdaq upon consummation of this offering. It is a condition to the closing of this offering that our common stock qualifies for listing on a national securities exchange. Following this offering, in order to maintain our listing on Nasdaq, we will be required to comply with certain rules of Nasdaq, including those regarding minimum stockholders’ equity, minimum share price, minimum market value of publicly held shares, and various additional requirements. Even if we initially meet the listing requirements and other applicable rules of Nasdaq, we may not be able to continue to satisfy these requirements and applicable rules. If we are unable to satisfy Nasdaq criteria for maintaining our listing, our securities could be subject to delisting.

If Nasdaq subsequently delists our securities from trading, we could face significant consequences, including:

• a limited availability for market quotations for our securities;

• reduced liquidity with respect to our securities;

• a determination that our common stock is a “penny stock,” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common stock;

• limited amount of news and analyst coverage; and

• a decreased ability to issue additional securities or obtain additional financing in the future.

If securities or industry analysts do not publish research or reports about our business, or if they publish a negative report regarding our common stock, the price of our common stock and trading volume could decline.

Any trading market for our common stock may depend in part on the research and reports that industry or securities analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade us, the price of our common stock would likely decline. If one or more of these analysts cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause the price of our common stock and the trading volume to decline.

Our management has broad discretion to determine how to use the funds raised in the offering and may use them in ways that may not enhance our results of operations or the price of our common stock.

We anticipate that we will use the net proceeds from this offering for general corporate purposes, including working capital, R&D, financing our marketing and operational expenses, upgrading our Company’s infrastructure, and international expansion. Our management will have significant discretion as to the use of the net proceeds to us from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the market price of our common stock.

We will be a “controlled company” within the meaning of the Nasdaq listing rules and are allowed to follow certain exemptions from certain corporate governance requirements that could adversely affect our public stockholders.

Table of Contents

underwriters’ over-allotment option. As a result, Karin Mei Huang, as the beneficial owner of the shares held by KMA Trust and KML Family Trust, will be able to exercise 90.9% of the aggregate voting power of our issued and outstanding shares of common stock and will be able to determine all matters requiring approval by our stockholders, immediately after the consummation of this offering. Under the Nasdaq listing rules, a company of which more than 50% of the voting power is held by an individual, group, or another company is a “controlled company” and is permitted to phase in its compliance with the independent committee requirements. Although we do not intend to rely on the “controlled company” exemptions under the Nasdaq listing rules even if we are a “controlled company,” we could elect to rely on these exemptions in the future. If we were to elect to rely on the “controlled company” exemptions, a majority of the members of our board of directors might not be independent directors and our nominating and corporate governance and compensation committees might not consist entirely of independent directors. Accordingly, if we rely on the exemptions, during the period we remain a controlled company and during any transition period following a time when we are no longer a controlled company, you would not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq.

We are an “emerging growth company” and a “smaller reporting company” under the JOBS Act, and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.

We are an “emerging growth company” and a “smaller reporting company” as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” and “smaller reporting companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the extended transition period for complying with new or revised accounting standards.

We will remain an “emerging growth company” until the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act, although we will lose that status sooner if our revenue exceeds $1.235 billion, if we issue more than $1 billion in non-convertible debt in a three-year period, or if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last day of our most recently completed second fiscal quarter.

We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) the market value of our common stock held by non-affiliates is equal to or less than $250 million as of the last business day of the most recently completed second fiscal quarter, or (ii) our annual revenue is equal to or less than $100 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is equal to or less than $700 million as of the last business day of the most recently completed second fiscal quarter.

We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. In addition, taking advantage of reduced disclosure obligations may make comparison of our financial statements with other public companies difficult or impossible. If investors are unable to compare our business with other companies in our industry, we may not be able to raise additional capital as and when we need it, which may materially and adversely affect our financial condition and results of operations.

Table of Contents

Nasdaq may apply additional and more stringent criteria for our initial and continued listing, since we plan to have a relatively small public offering and insiders will hold a large portion of our listed securities.

Nasdaq Listing Rule 5101 provides Nasdaq with broad discretionary authority over the initial and continued listing of securities on Nasdaq and Nasdaq may use such discretion to deny initial listing, apply additional or more stringent criteria for the initial or continued listing of particular securities, or suspend or delist particular securities based on any event, condition, or circumstance that exists or occurs that makes initial or continued listing of the securities on Nasdaq inadvisable or unwarranted in the opinion of Nasdaq, even though the securities meet all enumerated criteria for initial or continued listing on Nasdaq. In addition, Nasdaq has used its discretion to deny initial or continued listing or to apply additional and more stringent criteria in the instances, including: (i) where the company engaged an auditor that has not been subject to an inspection by the Public Company Accounting Oversight Board of the United States (the “PCAOB”), an auditor that PCAOB cannot inspect, or an auditor that has not demonstrated sufficient resources, geographic reach, or experience to adequately perform the company’s audit; (ii) where the company planned a small public offering, which would result in insiders holding a large portion of the company’s listed securities (in which instance, Nasdaq was concerned that the offering size was insufficient to establish the company’s initial valuation, and there would not be sufficient liquidity to support a public market for the company); and (iii) where the company did not demonstrate sufficient nexus to the U.S. capital market, including having no U.S. shareholders, operations, or members of the board of directors or management. Since we plan to have a relatively small public offering and our insiders will hold a large portion of our listed securities, Nasdaq may apply additional and more stringent criteria for our initial and continued listing, which may cause delay or even denial of our listing application.

We have preferred stock authorized, which can be designated by the Company’s board of directors without stockholder approval.

The Company has 100,000,000 shares of preferred stock authorized. The shares of preferred stock of the Company may be issued from time to time in one or more series, each of which shall have a distinctive designation or title as shall be determined by the board of directors of the Company prior to the issuance of any shares thereof. The preferred stock shall have such voting powers, full or limited, or no voting powers, and such preferences and relative, participating, optional, or other special rights and such qualifications, limitations, or restrictions thereof as adopted by the board of directors. Because the board of directors is able to designate the powers and preferences of the preferred stock without the vote of a majority of the Company’s stockholders, stockholders of the Company will have no control over what designations and preferences the Company’s preferred stock will have. The issuance of shares of preferred stock or the rights associated therewith, could cause substantial dilution to our existing stockholders. Additionally, the dilutive effect of any preferred stock which we may issue may be exacerbated given the fact that such preferred stock may have voting rights and/or other rights or preferences which could provide the preferred stockholders with substantial voting control over us and/or give those holders the power to prevent or cause a change in control, even if that change in control might benefit our stockholders. As a result, the issuance of shares of preferred stock may cause the value of our securities to decrease.

Anti-takeover provisions in our Articles of Incorporation and our Bylaws, as well as provisions of Nevada law, might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.

Our Articles of Incorporation, Bylaws and Nevada law contain provisions that may discourage, delay, or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or delay attempts by our stockholders to replace or remove our management. Our corporate governance documents include the following provisions:

• requiring advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for nominations of candidates for election to our board of directors; and

• subject to the rights of the holders of any outstanding series of preferred stock and unless otherwise required by law or resolution of our board of directors, vacancies on the board of directors arising through death, resignation, disqualification or removal, an increase in the number of directors, or otherwise may be filled by a majority of the directors then in office, though less than a quorum.

Table of Contents

Any provision of our Articles of Incorporation, as amended or Bylaws or Nevada law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.

The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition.

The sale of a significant number of our shares may cause the market price of our common stock to drop significantly.

Upon completion of this offering, all of our directors and executive officers and the holders of 5% or greater of our capital stock will have signed lock-up agreements that prevent them from selling any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, subject to certain exceptions, for a period of not less six months from the date of this prospectus without the prior written consent of the underwriters. The underwriters may in their sole discretion and at any time without notice release some or all of the shares subject to lock-up agreements prior to the expiration of the period. When determining whether or not to release shares from the lock-up agreements, the underwriters will consider, among other factors, the stockholder’s reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time.

Based on shares of our capital stock outstanding as of the date of this prospectus, we will have 44,000,000 shares of common stock outstanding after the completion of this offering, including the 4,000,000 shares of common stock that we are selling in this offering (representing 9.1% of our outstanding shares of common stock following the offering), which may be resold in the public market immediately. Additionally, beginning six months after the date of this prospectus, the remainder of the shares of our common stock will be eligible for sale in the public market due to the expiration of the lock-up agreements between our directors and executive officers and the holders of 5% or greater of our capital stock and the underwriters, unless US Tiger Securities, Inc., as representative of the several underwriters (the “Representative”) waives the provisions of these lock-up agreements and allows these stockholders to sell their shares earlier.

If our stockholders sell substantial amounts of our common stock in the public market, the market price of our common stock could decrease significantly. The perception in the public market that our stockholders might sell shares of our common stock could also depress the market price of our common stock. We cannot predict the effect, if any, of future sales of our common stock on the value of our common stock. Sales of substantial amounts of our common stock by large stockholders, or the perception that such sales could occur, may adversely affect the market price of our common stock.

The market price for shares of our common stock may drop significantly when such securities are sold in the public market. A decline in the price of shares of our common stock may impede our ability to raise capital through the issuance of additional shares of our common stock or other equity securities.

Table of Contents

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements that reflect our current expectations and views of future events, all of which are subject to risks and uncertainties. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. You can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may,” or other similar expressions in this prospectus. These statements are likely to address our growth strategy, financial results, and development programs. You must carefully consider any such statements and should understand that many factors could cause actual results to differ from our forward-looking statements. These factors may include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to:

• assumptions about our future financial and operating results, including revenue, income, expenditures, cash balances, and other financial items;

• our ability to execute our growth strategies, including our ability to meet our goals;

• current and future economic and political conditions;

• our capital requirements and our ability to raise any additional financing which we may require;

• our ability to attract clients and further enhance our brand recognition;

• changes to our board of directors and management and our ability to identify and hire a qualified permanent Chief Executive Officer on a timely basis;

• our ability to hire and retain qualified management personnel and key employees in order to enable us to develop our business;

• trends and competition in the herbal supplement industry; and

• other assumptions described in this prospectus underlying or relating to any forward-looking statements.

We describe certain material risks, uncertainties, and assumptions that could affect our business, including our financial condition and results of operations, under “Risk Factors.” We base our forward-looking statements on our management’s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may, and are likely to, differ materially from what is expressed, implied, or forecast by our forward-looking statements. Accordingly, you should be careful about relying on any forward-looking statements. Except as required under the federal securities laws, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this prospectus, whether as a result of new information, future events, changes in assumptions, or otherwise.

Table of Contents

Use of Proceeds

We estimate that the net proceeds to us from the sale of our shares of common stock in this offering will be approximately $14.5 million, assuming an initial public offering price of $4.0 per share after deducting underwriting discounts, non-accountable expense allowance, and estimated offering expenses. Our net proceeds will increase by approximately $2.1 million if the underwriters’ over-allotment option to purchase additional shares of common stock is exercised in full (based on the same assumed offering price as described in the preceding sentence).

We currently intend to use the net proceeds we receive from this offering as follows:

• approximately 31%, or $4.5 million assuming no over-allotment option is exercised, or $5.2 million if the over-allotment option is exercised in full, for general corporate purposes, including working capital to support day-to-day operations, such as for payroll, rent, insurance, inventory deposits;

• approximately 24%, or $3.5 million assuming no over-allotment option is exercised, or $4.0 million if the over-allotment option is exercised in full, for R&D, including research collaborations (for instance, our three milestone based agreements with City of Hope through mid-2026, including all animal work), research study expansions, refining newly developed products, including self-affirmed GRAS dossiers for two additional extracts, and funding pilot production of next generation BioPrecision products based on our White Button Mushroom extracts (i.e., WBM REx);

• approximately 20%, or $2.9 million assuming no over-allotment option is exercised, or $3.4 million if the over-allotment option is exercised in full, to finance the marketing and operational expenses for direct-to-consumer channel growth, physician outreach, and market expansion, including new hiring of eight field sales representatives, expansion of online advertising and launch of three educational road shows in the following 15 months, and we anticipate to require approximately $3 million of additional working capital to scale these programs for profitability;

• approximately 18%, or $2.6 million assuming no over-allotment option is exercised, or $3.0 million if the over-allotment option is exercised in full, to upgrade our Company’s infrastructure, such as our next generation DirecTCM platform integrated with leading electronic health records and other healthcare platforms, including hiring more internal software engineers and increasing Amazon Web Services and cloud storage capacity to support internal technologies and integrations with third-party suppliers and vendors, such as UPS, FedEx, USPS, and third-party logistics and warehouse providers in the following 24 months; and

• approximately 7%, or $1.0 million assuming no over-allotment option is exercised, or $1.2 million if the over-allotment option is exercised in full, for international expansion to expand our DirecTCM platform service to Asian and European markets, and we expect that a full commercial roll out will require approximately $2 million of additional capital.

The foregoing represents our current intentions with respect to the use and allocation of the net proceeds of this offering based upon our present plans and business conditions, but our management will have significant flexibility and discretion in applying the net proceeds. The occurrence of unforeseen events or changed business conditions could result in the application of the net proceeds of this offering in a manner other than as described above. Pending our use of the net proceeds as described above, we intend to invest the net proceeds in short-term bank deposits or interest-bearing, investment-grade securities.

Table of Contents

Dividend Policy

As of the date of this prospectus, we have not paid any cash dividends on our common stock, and our board of directors intends to continue a policy of retaining earnings, if any, for use in our operations. We are organized under the Nevada Revised Statutes (the “NRS”), which prohibits the payment of a dividend if, after giving it effect, we would not be able to pay our debts as they become due in the usual course of business or our total assets would be less than the sum of our total liabilities. Any determination by our board of directors to pay dividends in the future to stockholders will be dependent upon our operational results, financial condition, capital requirements, business projections, general business conditions, statutory and regulatory restrictions, and any other factors deemed appropriate by our board of directors.

Table of Contents

Capitalization

The following table sets forth our cash and capitalization as of December 31, 2025, on:

• an actual basis;

• an as-adjusted basis, after giving effect to the sale of 4,000,000 shares of our common stock in this offering at an assumed public offering price of $4.0 per share, and our receipt of the estimated $14.5 million in net proceeds from this offering assuming no over-allotment option is exercised, after deducting underwriting discounts, non-accountable expense allowance, and estimated offering expenses payable by us.

You should read this capitalization table together with “Use of Proceeds,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our financial statements and the related notes appearing elsewhere in this prospectus.

	Actual			As-Adjusted
Cash	$	1,962,303		$	16,484,246
Long-term loan – related party	$	4,600,000		$	4,600,000

Stockholders’ equity:
Common stock (par value $0.0001 per share), 40,000,000 and 44,000,000 shares issued and outstanding as of December 31, 2025, on an actual and as-adjusted basis, respectively		4,000			4,400
Additional paid-in capital		4,432,507			19,001,636
Accumulated deficit		(7,339,948	)		(7,556,414	)
Total stockholders’ (deficit) equity	$	(2,903,441	)	$	11,449,622

Total capitalization	$	1,696,559		$	16,049,622

A $1.00 increase (decrease) in the assumed initial public offering price of $4.0 per share of common stock, would increase (decrease) each of our as-adjusted cash, additional paid-in capital, total stockholders’ equity, and total capitalization by approximately $3.7 million, after deducting estimated underwriting discounts, non-accountable expense allowance, and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1 million shares in the number of shares of common stock offered by us would increase (decrease) each of our as-adjusted cash, additional paid-in capital, total stockholders’ equity and total capitalization by approximately $3.7 million, after deducting estimated underwriting discounts, non-accountable expense allowance, and estimated offering expenses payable by us.

Table of Contents

Dilution

Purchasers of our common stock in this offering will experience an immediate dilution of net tangible book value per share from the initial public offering price. Dilution in net tangible book value per share represents the difference between the amount per share paid by the purchasers of shares of common stock and the net tangible book value per share immediately after this offering.

As of December 31, 2025, our net tangible book value was approximately $(3.5) million, or $(0.09) per share of common stock. Net tangible book value per share represents our total tangible assets, less our total liabilities, divided by the number of outstanding shares of our common stock.

Dilution in net tangible book value per share of common stock represents the difference between the public offering price per share of our common stock in this offering and the adjusted net tangible book value per share of our common stock after giving effect to this offering. After giving effect to the sale of shares of common stock in this offering at an assumed offering price of $4.0 per share, and after deducting underwriting discounts, non-accountable expense allowance, and estimated offering expenses payable by us, our as-adjusted net tangible book value would have been $0.25 per share. This represents an immediate increase in net tangible book value of $0.34 per share to our existing stockholders and immediate dilution of $3.75 per share to new investors purchasing shares at the proposed public offering price. The following table illustrates the dilution in net tangible book value per share to new investors as of December 31, 2025:

Assumed initial public offering price per share of common stock	$	4.0
Net tangible book value per share of common stock as of December 31, 2025	$	(0.09	)
Increase in net tangible book value per share of common stock attributable to this offering	$	0.34
As-adjusted net tangible book per share of common stock as of December 31, 2025, after this offering	$	0.25
Dilution per share of common stock to investors participating in this offering	$	3.75

The dilution information discussed above is illustrative only and may change based on the actual initial public offering price and other terms of this offering. A $1.00 increase (decrease) in the assumed initial public offering price of $4.0 per share of common stock would increase (decrease) our as-adjusted net tangible book value per share after this offering by approximately $0.42 per share and increase (decrease) the dilution to new investors by $4.67 per share, and after deducting estimated underwriting discounts. Similarly, each increase or decrease of 1 million shares in the number of shares of common stock offered by us would increase (decrease) our as-adjusted net tangible book value by approximately $0.42 per share and decrease (increase) the dilution to new investors by approximately $3.67 per share, in each case assuming the assumed initial public offering price of $4.0 per share of common stock remains the same, and after deducting estimated underwriting discounts, non-accountable expense allowance, and estimated offering expenses.

If the underwriters exercise their option to purchase additional shares of common stock in full, the net tangible book value per share, as adjusted to give effect to this offering, would be $0.32 per share, and the dilution in net tangible book value per share to investors in this offering would be $3.68 per share.

The following table sets forth, as of December 31, 2025, the number of shares of common stock purchased from us, the total consideration paid to us and the average price per share paid by the existing holders of our common stock and the price to be paid by new investors in this offering at an assumed initial public offering price of $4.0 per share, before deducting estimated underwriting discounts, non-accountable expense allowance, and estimated offering expenses.

	Shares Purchased			Total Consideration				Average Price Per Share
Over-allotment option not exercised	Number	Percent		Amount		Percent		Average Price Per Share
Existing stockholders before this offering	40,000,000	90.9	%	$	4,436,507	21.7	%	$	0.11
Investors purchasing shares in this offering	4,000,000	9.1	%		16,000,000	78.3	%		4.00
Total	44,000,000	100.0	%	$	20,436,507	100.0	%	$	0.46

	Shares Purchased			Total Consideration				Average Price Per Share
Over-allotment option exercised in full	Number	Percent		Amount		Percent		Average Price Per Share
Existing stockholders before this offering	40,000,000	89.7	%	$	4,436,507	19.4	%	$	0.11
Investors purchasing shares in this offering	4,600,000	10.3	%		18,400,000	80.6	%		4.00
Total	44,600,000	100.0	%	$	22,836,507	100.0	%	$	0.51

Table of Contents

Management’s Discussion and Analysis of
Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included in this prospectus. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See “Disclosure Regarding Forward-Looking Statements” for a discussion of the uncertainties, risks and assumptions associated with these statements. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” and elsewhere in this prospectus.

Key Factors Affecting Results of Operations

The business, financial condition, and results of operations of the Company have been, and are expected to continue to be, affected by a number of factors, which primarily include the following:

Expand customer base and increase average revenue per customer

The growth of our revenue will depend on our ability to retain and increase customers. For the three months ended December 31, 2025 and 2024, we had 148 and 73 customers, respectively, with average revenue per customer of approximately $1,254 and $2,038, respectively. For the fiscal years ended September 30, 2025 and 2024, we had 163 and 199 customers, respectively, with average revenue per customer of approximately $4,500 and $4,000, respectively. Customer purchases made through the Amazon and TikTok e-commerce platforms are aggregated and presented as one account for each platform in these customer totals. Our DirecTCM platform was officially launched in May 2025 and it had 108 active healthcare providers as of December 31, 2025.

We monitor the number of existing and new customers as indicators of the growth of the overall business. Our ability to increase the number of customers and average revenue per customer will depend on our ability to build up the awareness of our brand. Moving forward, we plan to increase our investment in marketing and build up a bigger sales team.

The ability to secure supply and control costs

Historically, we have developed business relationships with approximately four suppliers (including one related party), most of which we have had for a significant period of time. For the three months ended December 31, 2025, two related party and one vendor accounted for 73%, 16%, and 11% of the Company’s total purchases, respectively. For the three months ended December 31, 2024, one related party and one vendor accounted for 71% and 15% of the Company’s total purchases, respectively. For the fiscal year ended September 30, 2025, five vendors accounted for 44%, 18%, 15%, 11%, and 10% of the Company’s total purchases, respectively. For the fiscal year ended September 30, 2024, one related party and one vendor accounted for 83% and 11% of the Company’s total purchases, respectively. We believe that these supplier relationships provide us reliable access to inventory, volume purchasing benefits, and the ability to deliver a diverse product offering cost-effectively.

In 2025, the U.S. government has implemented substantial tariffs on a wide range of goods imported from China under various authorities. This may negatively impact our results of operations. See “Risk Factors — Economic, Political, and Market Risks — We rely on third-party contract manufacturers located in China to produce our supplements, making us highly vulnerable to U.S. tariffs, trade disputes, and other disruptions related to U.S. — China trade relations, which could significantly increase our costs and materially harm our business.”

Focus on product portfolio and product mix with proprietary ingredients

Our product offerings span various categories, including nutritional supplements, herb extracts, and herbal tea, with diverse sizes and concentrations to meet varied customer needs.

For the three months ended December 31, 2025, we offered 68 SKUs of products, compared to 80 SKUs of products for the three months ended December 31, 2024. For the fiscal year ended September 30, 2025, we offered 68 SKUs of products, compared to 80 SKUs of products for the fiscal year ended September 30, 2024. The decrease is consistent with our strategic direction, to phase out traditional, non-proprietary products in favor of a focused portfolio rooted in herbal and plant-based formulations.

Table of Contents

By discontinuing non-proprietary products in favor of our BioPrecision formulations, we aim to provide a product line rooted in herbal and plant-based ingredients. This approach aligns our offerings with our core strength in R&D for supplements, ensuring a streamlined portfolio that emphasizes quality.

Results of Operations

For the three months ended December 31, 2025 and 2024

The following table presents certain combined statement of operations information and presentation of that data as a percentage of change from year to year.

	For the Three Months Ended December 31, 2025 (Unaudited)			For the Three Months Ended December 31, 2024 (Unaudited)			Variance
Revenue	$	185,638		$	148,786		24.77	%
Cost of revenue		42,474			58,742		(27.69	)%
Gross profit		143,164			90,044		58.99	%
Selling expenses		84,578			76,376		10.74	%
General and administrative expenses		602,873			530,447		13.65	%
Research and development expenses		61,375			15,000		309.17	%
Loss from operations		(605,662	)		(531,779	)	13.89	%
Other income (expense), net		(94,578	)		128,720		(173.48	)%
Loss before income taxes		(700,240	)		(403,059	)	73.73	%
Income tax expenses		—			—		—	%
Net loss	$	(700,240	)	$	(403,059	)	73.73	%
Gross profit % of revenue		77.12	%		60.52	%
Net loss % of revenue		(377.21	)%		(270.9	)%

Revenue

Revenue for the three months ended December 31, 2025 increased by 24.77% to approximately $0.2 million, compared to approximately $0.1 million for the three months ended December 31, 2024. The increase was mainly due to our strategic restructuring of our product lines to emphasize higher-potential offerings and the successful development of new OEM customer relationships.

For the three months ended December 31, 2025 and 2024, we had 148 and 73 customers, respectively, including 42 wholesale and 106 retail customers for the three months ended December 31, 2025, and 41 wholesale and
32 retail customers for the same period in 2024. Retail customer purchases made through the Amazon and TikTok e-commerce platforms are aggregated and presented as one account for each platform in these customer totals.

The increase in the total number of customers was primarily attributable to growth in retail customers driven by the pilot VIP membership program in the DirecTCM platform. The number of our wholesale customers increased, and average revenue per wholesale customer increased by 15.78% to approximately $3,000 for the three months ended December 31, 2025 as compared to approximately $2,000 for the same period in 2024. In contrast, average revenue per retail customer decreased by 59.85% to approximately $700 for the three months ended December 31, 2025, compared to approximately $2,000 for the same period in 2024, primarily attributable to changes in customer purchasing behavior. During the three months ended December 31, 2025, a larger number of retail customers made smaller-quantity purchases, resulting in lower average transaction values. In contrast, during the three months ended December 31, 2024, retail customers generally purchased higher quantities per order, leading to higher average order values and overall retail revenue. Sales of dietary supplements are largely driven by customer demand and individual preferences, which are inherently variable and difficult to predict. As a result, sales patterns may fluctuate from period to period and may not follow a consistent or predictable trend.

Table of Contents

Refining Our Product Mix:

We reduced the range of our existing products to place greater emphasis on our BioPrecision formulation product line, which we began selling in July 2024. Our revenue from our product categories is summarized as follows:

	For the Three Months Ended December 31,								Change USD		Change %
Product Categories	2025		%		2024		%		Change USD		Change %
BioPrecision formulation	$	65,152	35.10	%	$	55,604	37.37	%	$	9,548	17.17	%
Dietary supplements (under Farlong brand)		106,744	57.50	%		87,035	58.50	%		19,709	22.65	%
Herbal extract powders		12,215	6.58	%		6,147	4.13	%		6,068	98.71	%
Subscription revenue		1,527	0.82	%		—	—			1,527	100.00	%
Total	$	185,638	100.00	%	$	148,786	100.00	%	$	36,852	24.77	%

The BioPrecision formulation product line has resonated strongly with both healthcare providers and consumers, validating our focus on premium, science-backed supplements. In line with our refined product strategy as mentioned above, BioPrecision formulation products generated approximately $65,000 and $56,000 in revenue for the three months ended December 31, 2025 and 2024, respectively.

Revenue from dietary supplements was approximately $0.1 million and $87,000 for the three months ended December 31, 2025 and 2024, respectively, representing an increase of approximately $20,000. The increase was primarily attributable to increased promotional efforts related to the nutritional supplement product line, which contributed to higher sales volume during the current period.

Revenue from herbal extract powders increased by approximately $6,000. Revenue from herbal extract powders remained a small portion of our overall revenue for the three months ended December 31, 2025 and 2024 and it is not expected to become significant in 2025 and beyond.

As DirecTCM platform remains in the early stages of development and commercialization, we generated limited subscription revenue through the pilot VIP membership program for the three months ended December 31, 2025.

Expanding Sales Channels:

We provide OEM white-label services, enabling existing customers to expand their businesses under their own brands. During the three months ended December 31, 2025, two customers utilized our OEM white-label services, resulting in approximately $13,652 revenue, compared to approximately $25,000 for the three months ended December 31, 2024. While limited revenue was generated from OEM white-label services during the period, we continued to leverage healthcare platforms to broaden market reach and support our overall business strategy, complementing our existing partnerships with retail chain operators.

Cost of Revenue

Cost of revenue for the three months ended December 31, 2025 decreased by 27.69% to approximately $42,000 compared to approximately $59,000 for the same period in 2024. This decrease was primarily driven by decrease in costs for BioPrecision formulation products by 54.36%. Despite an increase in revenue from BioPrecision products during the three months ended December 31, 2025, cost of revenue declined due to lower unit costs. In the prior period, the Company recorded inventory obsolescence charges for certain slow-moving BioPrecision products, which reduced the carrying value of those inventories. As a result, when such inventories were subsequently sold in the current period, the related cost of goods sold was lower compared to the prior period. Cost of revenue for dietary supplements under the Farlong brand increased by 59.21%, which was primarily attributable to higher sales volume during the current period.

Product Categories	For the Three Months Ended December 31,								Change USD			Change %
Product Categories	2025		%		2024		%		Change USD			Change %
BioPrecision formulation	$	20,569	48.43	%	$	45,071	76.73	%	$	(24,502	)	(54.36	)%
Dietary supplements (under Farlong brand)		21,743	51.19	%		13,657	23.25	%		8,087		59.21	%
Herbal extract powders		162	0.38	%		14	0.02	%		147		1,000.14	%
Total cost of revenue	$	42,474	100.00	%	$	58,742	100.00	%	$	(16,268	)	(27.69	)%

Table of Contents

Gross Profit

Gross profit was approximately $143,000 for the three months ended December 31, 2025 compared to approximately $90,000 for the same period in 2024, The increase was primarily attributable to higher revenue from dietary supplements and lower of cost of revenue related to BioPrecision formulation products.

The gross margin increased to 77.12% for the three months ended December 31, 2025 from 60.52% in the same period of 2024. The increase in gross margin was due to an increase in gross margin of BioPrecision formulation product line, which was 68.43% for the three months ended December 31, 2025 compared to 18.94% for the same period in 2024. This increase was mainly due to lower cost of revenue, as certain slow-moving inventories were written down in the prior period, resulting in a reduced carrying value. Consequently, when such inventories were sold during the current period, the associated cost of goods sold was lower, leading to higher gross margins. The increase of gross margin was offset by a decrease in gross margin for dietary supplements under the Farlong brand, which declined to 79.63% for the three months ended December 31, 2025 from 84.30% for the same period in 2024. The decrease was primarily attributable to increased promotional pricing strategies implemented during the current period relative to the prior period to stimulate sales growth. During the three months ended December 31, 2025 and 2024, we offered promotional discounts of approximately $15,000 and $11,000, respectively. While these increased promotional programs contributed to higher sales volume and increased revenue, the reduced average selling prices per unit negatively impacted the gross margin for dietary supplements during the current period.

Selling Expenses

Selling expenses mainly consist of payroll of our sales team, advertising and promotion expenses, and expenses for samples or free gifts. Selling expenses increased by 10.74% to approximately $85,000 for the three months ended December 31, 2025 from approximately $76,000 for the same period in 2024. The increase was primarily attributable to an increase of approximately $11,000 in advertising and promotion expenses, which was due to initial marketing efforts on Amazon for the launch of the new BioPrecision product line, offset by a slight decrease of approximately $2,000 in payroll and compensation expenses of our sales team and a decrease of approximately $200 related to samples and free gifts due to promotion activities,

General and Administrative Expenses

General and administrative expenses increased by 13.65% for the three months ended December 31, 2025 compared to the same period in 2024. The increase was primarily attributable to an increase in professional fees of approximately $0.1 million related to the initial public filing, and the increase in general and office expenses of approximately $16,000, offset by a decrease of approximately $18,000 in software expenses, and the decrease of approximately $14,000 payroll and compensation expenses.

Research and Development Expenses

Research and development expenses increased to approximately $61,000 for the three months ended December 31, 2025, from $15,000 for the same period in 2024. The increase was primarily due to preclinical trials related to the development of multiple products that we initiated under a research agreement signed on October 7, 2024, with City of Hope.

Other Income (Expense), net

Our other income (expense), net is summarized as follows:

	For the Three Months Ended December 31, 2025 (Unaudited)			For the Three Months Ended December 31, 2024 (Unaudited)			Change (%)
Other Income (Expense), net
Interest expense		(108,951	)		(23,685	)	360.00	%
Employee retention tax credit		—			101,662		(100.00	)%
Other income, net		14,373			50,743		(71.68	)%
Total Other Income (Expense), net	$	(94,578	)	$	128,720		(173.48	)%

Table of Contents

Total other expense, net was approximately $95,000 for the three months ended December 31, 2025 as compared to other income of approximately $0.1 million for the three months ended December 31, 2024. The change was mainly attributable to employee retention tax credit received in connection with a prior-period claim of approximately $0.1 million, a decrease in realized investment gain of approximately $46,000, and the increase of interest expense of approximately $85,000 due to an additional loan acquired from a related party during the three months ended December 31, 2025.

Provision for Income Taxes

We did not incur any current tax provision for the three months ended December 31, 2025 and 2024 due to losses before income tax. Our deferred tax provision was also nil as we provided a full valuation allowance for our deferred tax assets, which mainly consisted of net operating losses.

Net Loss

Net loss for the three months ended December 31, 2025 was approximately $0.7 million compared to approximately $0.4 million for the same period in 2024, representing a decrease of approximately $0.3 million. The decrease was primarily driven by a decrease in other income of approximately $0.2 million, an increase in general and administrative expenses of approximately $72,000, and an increase in research and development expense of approximately $46,000, offset by the increase in revenue of approximately $37,000 and the decrease in cost of revenue of approximately $16,000.

Results of Operations

For the fiscal years ended September 30, 2025 and 2024

The following table presents certain combined statement of operations information and presentation of that data as a percentage of change from year to year.

	For the Fiscal Year Ended September 30, 2025			For the Fiscal Year Ended September 30, 2024			Variance
Revenue	$	725,806		$	765,509		(5.19	)%
Cost of revenue		288,090			296,114		(2.71	)%
Gross profit		437,716			469,395		(6.75	)%
Selling expenses		450,626			159,553		182.43	%
General and administrative expenses		2,419,338			2,287,093		5.78	%
Research and development expenses		106,375			—		100	%
Loss from operations		(2,538,623	)		(1,977,251	)	28.39	%
Other (expense) income, net		(16,899	)		21,289		(179.38	)%
Loss before income taxes		(2,555,522	)		(1,955,962	)	30.65	%
Income tax expenses		—			—		—	%
Net loss	$	(2,555,522	)	$	(1,955,962	)	30.65	%
Gross profit % of revenue		60.31	%		61.32	%
Net loss % of revenue		(352.09	)%		(255.51	)%

Revenue

Revenue for the fiscal year ended September 30, 2025 decreased by approximately 5.19% to $0.7 million, compared to $0.8 million for the fiscal year ended September 30, 2024. The decline was primarily attributable to our decision to streamline the product line by discontinuing non-proprietary products in favor of our BioPrecision formulations.

Table of Contents

For the fiscal years ended September 30, 2025 and 2024, we had 163 and 199 customers, respectively, including 67 and 74 wholesale customers and 96 and 125 retail customers, respectively. Retail customer purchases made through the Amazon and TikTok e-commerce platforms are aggregated and presented as one account for each platform in these customer totals.

The decrease in the total number of customers was mainly attributable to the reduction of our product mix to phase out some older and less marketable products. The average revenue per wholesale customer decreased by 26.48% to approximately $7,000 for the fiscal year ended September 30, 2025 as compared to approximately $9,000 for the same period in 2024, primarily due to the Company’s streamlining of its product line, which resulted in a reduced variety of products available to wholesale customers, and the average revenue per retail customer increased by 248.36% to approximately $3,000 for the fiscal year ended September 30, 2025 as compared to approximately $1,000 for the same period in 2024. The increase in average revenue per retail customer was attributed to the rising demand for our new products from new product mix and expanding sales channels.

Refining Our Product Mix:

	For the Fiscal Years Ended September 30,								Change USD			Change %
Product Categories	2025		%		2024		%		Change USD			Change %
BioPrecision formulation	$	323,171	44.53	%	$	177,271	23.16	%	$	145,900		82.30	%
Dietary supplements (under Farlong brand)		359,324	49.51	%		446,406	58.31	%		(87,081	)	(19.51	)%
Herbal extract powders		41,920	5.77	%		141,832	18.53	%		(99,913	)	(70.44	)%
Subscription revenue		1,391	0.19	%		—	—			1,391		100.00	%
Total revenue	$	725,806	100.00	%	$	765,509	100.00	%	$	(39,703	)	(5.19	)%

The BioPrecision formulation product line has resonated strongly with both healthcare providers and consumers, validating our focus on premium, science-backed supplements. In line with our refined product strategy as mentioned above, BioPrecision formulation products generated approximately $0.3 million in revenue for the fiscal year ended September 30, 2025.

Revenue from dietary supplements was approximately $0.4 million and $0.4 million for the fiscal years ended September 30, 2025 and 2024, respectively, representing a decrease of approximately $87,000. The decrease was primarily due to our deliberate reduction in product variety within the nutritional supplement line to shift focus toward the BioPrecision formulations.

Revenue from herbal extract powders decreased by approximately $0.1 million. Revenue from herbal extract powders remained a small portion of our overall revenue for the fiscal years ended September 30, 2025 and 2024 and it is not expected to become significant in 2025 and beyond.

Expanding Sales Channels:

We provide OEM white-label services, enabling existing customers to expand their businesses under their own brands. During the fiscal year ended September 30, 2025, two customers utilized our OEM white-label services, generating approximately $0.2 million in revenue, compared to $0.2 million for the fiscal year ended September 30, 2024. We also leveraged healthcare platforms to broaden our market reach, complementing our existing partnerships with retail chain operators.

Table of Contents

Cost of Revenue

Cost of revenue for the fiscal year ended September 30, 2025 decreased by 2.71% to approximately $0.3 million compared to approximately $0.3 million for the same period in 2024. This decrease was primarily driven by a 99.14% and 25.66% decrease in costs for herbal extract powders and dietary supplements, respectively, mainly attributable to the decrease of revenue from sales herbal extract powders and dietary supplements product. The decrease was offset by the increase from costs for BioPrecision formulation products by 44.08% due to the increase in the respective revenue.

Product Categories	For the Fiscal Years Ended September 30,								Change USD			Change %
Product Categories	2025		%		2024		%		Change USD			Change %
BioPrecision formulation	$	224,660	77.98	%	$	155,928	52.66	%	$	68,734		44.08	%
Dietary supplements (under Farlong brand)		62,953	21.85	%		84,684	28.60	%		(21,732	)	(25.66	)%
Herbal extract powders		477	0.17	%		55,502	18.74	%		(55,026	)	(99.14	)%
Total cost of revenue	$	288,090	100.00	%	$	296,114	100.00	%	$	(8,024	)	(2.71	)%

Gross Profit

Gross profit was approximately $0.4 million for the fiscal year ended September 30, 2025 compared to approximately $0.5 million for the same period in 2024. The decline was primarily driven by lower revenue from our herbal extract powder products and dietary supplements products for approximately $100,000 and $87,000, respectively, partially offset by an increase of approximately $0.1 million in revenue from BioPrecision formulation products.

Gross margin decreased to 60.31% for the fiscal year ended September 30, 2025 from 61.32% for the same period in 2024. The decrease was primarily attributable to the higher sales mix of the BioPrecision formulation product line, which carried a relatively lower gross margin of 30.48%. The lower margin reflects the Company’s strategy to evaluate market response and establish an initial presence in the market.

Selling Expenses

Selling expenses mainly consist of payroll of our sales team, advertising and promotion expenses, and expenses for trade shows. Selling expenses increased by 182.43% to approximately $0.5 million for the fiscal year ended September 30, 2025 from approximately $0.2 million for the same period in 2024. The increase was primarily attributable to an increase of approximately $0.4 million in advertising and promotion expenses, which was due to initial marketing efforts on TikTok for the launch of the new BioPrecision product line.

General and Administrative Expenses

General and administrative expenses increased by 5.78% to approximately $2.4 million for the fiscal year ended September 30, 2025 compared to approximately $2.3 million the same period in 2024. The increase was primarily attributable to an increase in printing, postage, and delivery expenses of approximately $79,000 and an increase of approximately $0.1 million in product certification, insurance, and services fee in support of our operations, offset by a decrease of approximately $0.1 million in software expense.

Research and Development Expenses

Research and development expenses increased to approximately $0.1 million for the fiscal year ended September 30, 2025, from nil for the same period in 2024. The increase was primarily due to preclinical trials related to the development of multiple products that we initiated under a research agreement signed on October 7, 2024, with City of Hope.

Table of Contents

Other Income (Expense), net

Our other income (expense), net is summarized as follows:

	For the Fiscal Year Ended September 30, 2025			For the Fiscal Year Ended September 30, 2024			Change (%)
Other Income (Expense), net
Dividend/interest income		7,252			4,270		69.84	%
Employee retention tax credit		101,661			—		100.00	%
Interest expense		(175,529	)		(3,904	)	4,396.13	%
Other income, net		49,717			20,923		137.62	%
Total Other Income (Expense), net	$	(16,899	)	$	21,289		(179.38	)%

Total other expense, net was approximately $17,000 for the fiscal year ended September 30, 2025 as compared to other income of approximately $21,000 for the fiscal year ended September 30, 2024. The change was mainly attributable to an increase in interest expense of approximately $0.2 million due to additional loans acquired from a related party during the fiscal year ended September 30, 2025, offset by employee retention tax credit received in connection with a prior-period claim of approximately $0.1 million.

Provision for Income Taxes

We did not incur any current tax provision for the fiscal years ended September 30, 2025 and 2024 due to losses before income tax. Our deferred tax provision was also nil as we provided a full valuation allowance for our deferred tax assets, which mainly consisted of net operating losses.

Net Loss

Net loss for the fiscal year ended September 30, 2025 was approximately $2.6 million compared to approximately $2.0 million for the same period in 2024, representing an increase of approximately $0.3 million. The increase was primarily driven by the increase in selling expenses of approximately $0.3 million, the increase in general and administrative expenses of approximately $0.1 million, the increase in research and development expenses of approximately $0.1 million, and the decrease in other income, net of approximately $38,000.

LIQUIDITY AND CAPITAL RESOURCES

In assessing liquidity, we monitor and analyze our cash on-hand and operating expenditure commitments. Our liquidity needs are to meet working capital requirements and operating expense obligations. To date, we have financed our operations primarily through cash flows from operations and debt financing from related parties. As of December 31, 2025 and September 30, 2025, the Company had approximately $2.0 million and $2.5 million in cash and cash equivalent, respectively, which primarily consists of bank deposits, which are unrestricted as to withdrawal and use. As of December 31, 2025, our working capital and accumulated deficit were approximately $1.2 million and $7.3 million, respectively, compared to $1.9 million and $6.6 million, respectively, as of September 30, 2025. For the three months ended December 31, 2025, our negative operating cashflow was approximately $0.6 million.

We have experienced recurring losses from operations and negative cash flows from operating activities since 2022. In addition, we had, and may potentially continue to have, an ongoing need to raise additional cash from outside sources to fund our expansion plan and related operations. Successful transition to attaining profitable operations is dependent upon achieving a level of revenue adequate to support our cost structure. In connection with our assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that these conditions raise substantial doubt about our ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.

If we are unable to manage our business to have sufficient funds to operate within the normal operating cycle of a 12-month period, we may have to consider certain cost cutting measure to reduce our operating costs. We may also consider supplementing our available sources of funds through the issuance of additional debt and equity financing.

Table of Contents

We can make no assurances that required financings will be available for the amounts needed, or on terms commercially acceptable to us, if at all. If one or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there would likely be a material adverse effect on us and it would materially and adversely affect our ability to continue as a going concern. As a result, investors or other financing sources may be unwilling to provide funding to us on commercially reasonable terms or at all.

The unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. However, if we are unable to continue as a going concern, we may have to discontinue operations and liquidate our assets and may be compelled to receive less than the value at which those assets are carried on our consolidated audited financial statements, which would cause the stockholders to lose all or a part of their investment.

The following table sets forth our selected consolidated cash flow data for the periods indicated:

	For the Three Months Ended December 31,
	2025 (Unaudited)		2024 (Unaudited)
	US$		US$
Net cash used in operating activities	(600,245	)	(480,559	)
Net cash provided by (used in) investing activities	60,000		(71,553	)
Net cash used in financing activities	—		(2,753	)
Net decrease in cash and cash equivalents	(540,245	)	(554,865	)
Cash and cash equivalents, at the beginning of period	2,502,548		1,339,922
Cash and cash equivalents, at the end of period	1,962,303		785,057

	For the Fiscal Year Ended September 30,
	2025		2024
	US$		US$
Net cash used in operating activities	(2,250,279	)	(1,918,192	)
Net cash used in investing activities	(72,097	)	(96,409	)
Net cash provided by financing activities	3,485,002		980,833
Net increase (decrease) in cash and cash equivalents	1,162,626		(1,033,768	)
Cash and cash equivalents, at the beginning of year	1,339,922		2,373,690
Cash and cash equivalents, at the end of year	2,502,548		1,339,922

Operating Activities

Net cash used in operating activities was approximately $0.6 million for the three months ended December 31, 2025 and was primarily attributable to i) a net loss of approximately $0.7 million, and ii) approximately $50,000 decrease in operating lease liabilities due to timely payment, iii) approximately $37,000 decrease in accounts receivable, offset by i) increased other payables — related party of approximately $0.1 million, mainly due to additional long-term funding received from a related party due the period and ii) increased noncash operating lease expenses of approximately $51,000.

Net cash used in operating activities was approximately $2.3 million for the fiscal year ended September 30, 2025 and was primarily attributable to i) a net loss of approximately $2.6 million, and ii) approximately $0.2 million decrease in operating lease liabilities due to timely payment, offset by i) increased noncash operating lease expenses of approximately $0.2 million, and ii) increased other payables — related party of approximately $0.1 million, mainly due to additional long-term funding received from a related party due the period.

Net cash used in operating activities was approximately $2.0 million for the fiscal year ended September 30, 2024 and was primarily attributable to i) a net loss of approximately $2.0 million; and ii) increased inventory of approximately $0.7 million as we purchased new products, offset by increased accounts payable — related parties of approximately $0.7 million, which we have not yet paid for the purchase.

Table of Contents

Investing Activities

For the three months ended December 31, 2025, net cash used in investing activities amounted to approximately $60,000, which was proceeds from sale of equipment.

For the fiscal year ended September 30, 2025, net cash used in investing activities amounted to approximately $72,000, which was primarily for the purchase of property and equipment.

For the fiscal year ended September 30, 2024, net cash used in investing activities amounted to approximately $0.1 million, which was primarily for purchase of an automobile of approximately $0.1 million, offset by proceeds from trade in automobile of $25,000.

Financing Activities

Net cash used in financing activities was nil for the three months ended December 31, 2025.

Net cash used in financing activities was approximately $3.5 million for the fiscal year ended September 30, 2025, which was mainly due to long-term loan borrowing from related parties of $3.6 million, offset by payment of deferred offering cost of $0.1 million for our upcoming IPO and principal payment of finance lease of approximately $5,000.

Net cash provided by financing activities was approximately $1.0 million for the fiscal year ended September 30, 2024, which was due to long-term loan borrowing from related parties of $1.0 million, offset by payment of deferred offering cost of approximately $8,000 for our upcoming IPO and principal payment of finance lease of approximately $11,000.

Share Exchange Agreement

On December 27, 2023, we entered into a share exchange agreement with Longstar and its then sole stockholder, Karin Mei Huang, and issued 40,000,000 shares of common stock to Karin Mei Huang in exchange for 100% of the equity interest of Longstar. Before and after the reorganization, we, together with or subsidiary, are effectively controlled by the same stockholder, Karin Mei Huang, and therefore the reorganization is accounted as a recapitalization of entities under common control in accordance with Accounting Standards Codification (“ASC”) 805-50-25. Accordingly, for accounting purposes the combination was treated as the equivalent of Longstar issuing shares for the net assets of Farlong. The consolidation of us and our subsidiary has been accounted for at historical cost and prepared on the basis as if the aforementioned transaction had become effective as of the beginning of the first period presented in the accompanying consolidated financial statements in accordance with ASC 805-50-45-5.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures, or capital resources.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

We prepare our consolidated financial statements in accordance with U.S. GAAP and pursuant to the rules and regulations of the SEC. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated and combined financial statements and accompanying notes. Actual results could differ from those estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition and results of operations will be affected. We base our estimates on experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies, which we discuss further below. While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our consolidated financial statements.

Table of Contents

Revenue recognition

We follow ASC 606 Revenue Recognition and recognize revenue from product sales revenue, net of promotional discounts and return allowances, when the following revenue recognition criteria are met: a contract has been identified, separate performance obligations are identified, the transaction price is determined, the transaction price is allocated to separate performance obligations and revenue is recognized upon satisfying each performance obligation.

Product revenue

The accounting treatment for contracts with customers where the amounts charged per product is fixed and determinable, and the specific terms of the contracts were agreed on including payment terms which are typically 30 days for wholesale customers while retail customers are charged upon delivery on products, is described below. We have one performance obligation, which is to deliver products to customers. We transfer the risk of loss or damage upon shipment or customer pick up. Therefore, revenue from product sales is recognized at a point in time when control of products is transferred to customers and we have no further obligation to provide services related to such product. Consideration is reduced by sales discounts and return allowances which are recorded in the period in which the related sale is recognized. We provide a seven-day return policy and a limited warranty on our products. Return and warranty allowances, are based on our best estimate of expected product returns using historical experience which has been immaterial to us.

Subscription revenue

In June 2025, we launched the VIP membership program, under which we generate subscription revenue from non-refundable membership fees. The subscription revenue derived from newsletter service is recognized ratably over the membership period as the customer simultaneously receives and consumes the benefits.

We evaluate the criteria of ASC 606 — Revenue Recognition Principal Agent Considerations in determining whether it is appropriate to record the gross amount of product sales and related costs or the net amount earned as commissions. We concluded that because we are primarily responsible for fulfilling the promise to deliver products and we are subject to inventory risk before control of the good or service has been transferred to a customer and we have discretion in establishing the price, revenue is recorded at gross.

Return Policy, Warranty Risks, and Potential Impact on Financial Results

Inventory

Inventory consists of finished goods ready for sale and is stated at the lower of cost or net realizable value. We value our inventory using the first in first out costing method. We include as a part of cost of goods sold any freight incurred to ship the product from our vendors to warehouses. We regularly review inventory and consider forecasts of future demand, market conditions and product obsolescence.

If the estimated net realizable value of the inventory is less than cost, we make provisions in order to reduce our carrying value to its estimated net realizable value. We also review inventory for slow moving and obsolescence and record impairment for obsolescence. Impairment losses on inventory were approximately $12,000 and $5,000 for the three months ended December 31, 2025 and 2024, respectively, and approximately $37,000 and $27,000 for the fiscal years ended September 30, 2025 and 2024, respectively.

Recently issued accounting pronouncements

See Note 2 of the notes to the consolidated financial statements included elsewhere in this prospectus for a discussion of recently issued accounting standards.

Table of Contents

Business

Overview

We develop product formulations and engage contract manufacturers to produce our proprietary supplements, which we then market and distribute. Our brands engage in the sale of dietary supplements, encompassing herbal products through various sales arrangements. We are dedicated to providing authentic and personalized health solutions that meet a high standard of quality and consumer trust. We work to empower individuals with the knowledge, tools, and solutions needed to lead a life of optimal health and wellness.

• Notoginseng (Panax notoginseng) saponin extract;

• Breviscapine (Erigeron breviscapus) flavonoid extract;

• Polygonum capitatum extract;

• Innerpure formulation; and

• Rodgersia sambucifolia Hemsl. Extract.

The small-scale, preclinical studies we sponsor are being run entirely outside the purview of the U.S. FDA’s investigational-drug framework:

• they do not involve the administration of an “investigational new drug”;

• they are not being conducted pursuant to an IND;

• we have not filed, and do not presently intend to file, an IND or any other drug-related submission with the FDA; and

• the studies are not designed to serve as, or to be included in, an FDA drug-approval dossier.

Table of Contents

Our DirecTCM platform was officially launched in May 2025. As of December 31, 2025, our DirecTCM platform had approximately 30,000 pre-registered healthcare providers. We had 108 active healthcare providers on our DirecTCM platform as of December 31, 2025, which accounted for 0.36% of all pre-registered healthcare providers on our DirecTCM platform. The active healthcare providers refer to those healthcare providers who logged into our DirecTCM platform more than one time in the past 92 days (from October 1, 2025 to December 31, 2025) and used at least one clinical-decision or ordering feature on our DirecTCM platform as of December 31, 2025. As of December 31, 2025, the DirecTCM platform had approximately 65 healthcare providers enrolled in the pilot VIP membership program we launched in June 2025. See “— Recent Development.”

Our Competitive Strengths

We believe the following competitive strengths are essential for our success and differentiate us from our competitors:

Proprietary Technology and Intellectual Property

We attach great importance to technology R&D, advocate technological innovation, and insist on driving business development with technology. We hold significant trade secrets and proprietary knowledge in formulation-based product development and manufacturing. See “— Intellectual Property” for details.

Our DirecTCM platform leverages aggregated usage trends and 26 years of sales data to guide healthcare providers in recommending supplements tailored to individual wellness needs. By focusing on reorder rates, historical demand patterns, and real-world outcomes, DirecTCM generates insights that spur continuous product refinement and innovation. In addition, the platform integrates logistics data in real time, ensuring accurate inventory and delivery information so that healthcare providers and their patients can receive timely, efficient service.

Established Brand

Through Longstar, which was founded in 1999, Farlong has been active for over two decades in combining holistic herbal supplement with modern scientific approaches. This long-term presence has helped the Company build strong business relationships with our customers and vendors, especially among healthcare providers who appreciate clinically tested herbal solutions. Our reputation for quality and trust is built on years of rigorous research, development, and customer feedback. Farlong’s focus on plant-based ingredients and self-affirmed GRAS conclusion compliance positions the brand as a trusted, reliable source for herbal supplements. Clinical evidence (for instance, documented improvements in cardiovascular, cognitive, and digestive health) further enhances the brand’s standing with healthcare providers and consumers. See “— Research and Development — Research Studies” for details. Our multiple brands, such as Best Doctor Formula, Dr. Herbal Well, ACA Herb, ZEN Life Herb, and A PURE HERB, target different segments, including direct-to-consumer and healthcare providers. This multi-brand strategy facilitates deeper market penetration and brand-building across e-commerce, retail, and clinical settings.

Table of Contents

Large and Growing Customer Base

We have built a strong customer base through our long-standing presence in the market. As of December 31, 2025, our DirecTCM platform had approximately 30,000 pre-registered healthcare providers, of which 108 were active. According to an optional self-reported survey on our DirecTCM platform, the active healthcare providers each see a median of 20 patients per day, roughly 420 patients per month. Therefore, 108 active healthcare providers in total represent an estimated 45,360 patients encountered per month. Our DirecTCM platform’s provider-centered approach allows for exponential access to consumers of supplements. In addition, consumers seeking all-natural, clinically backed supplements are likely to grow as awareness of holistic herbal supplements and wellness solutions continues to rise globally. See “— Our Industry and Our Opportunity” for details.

Experienced Management Team with Strong Financial Expertise

Our CFO, Chiwen “Claire” Wang, brings a distinguished background in financial management and strategic leadership. Her extensive experience includes overseeing year-end audits, ensuring the accuracy and integrity of financial statements, and managing the auditing process for public companies — skills that are instrumental to guiding our financial strategy and supporting compliance with public company requirements. See “Management” in this prospectus for details.

Innovative Culture and R&D Capabilities

We prioritize integrating centuries-old herbal wisdom with modern clinical validation. This framework of combining “traditional knowledge + modern R&D” fuels product innovation and competitive advantage. DirecTCM data analytics, including patient feedback, usage patterns, and outcome measures, contribute to Farlong’s continual enhancement of formulations and new product pipelines. See “— Our Platform: DirecTCM.com” for details. This data-driven R&D, backed by 26 years of holistic herbal supplement research, accelerates iteration cycles and helps maintain the Company’s competitive edge in the health supplements market. We also collaborate with several external research institutions, such as City of Hope and the World Renew Medical Hospital to conduct high-quality research and trials. See “— Research and Development — Research Studies” for details.

Our Growth Strategies

We intend to develop our business and strengthen brand loyalty by implementing the following strategies:

Expansion Plans on DirecTCM Platform and Products

We see great potential in expanding services on our DirecTCM platform and promoting our products. We intend to explore additional market opportunities by widening product availability through major e-commerce platforms and retail partnerships, and will seek to facilitate business development and expansion with our customers. We market our products under the brands Best Doctor Formula, Dr. Herbal Well, and ACA Herb on leading e-commerce platforms, including Amazon.com. This strategic online presence aims to capture a significant share of the online supplements marketplace. We emphasize the expansion of product lines containing botanical extracts for which we have reached (or are pursuing) self-affirmed GRAS conclusions, including Ginseng Plus, LifeFlower Breviscapine, Polygonum capitatum, and InnerPure. By leveraging the power of digital marketing and e-commerce, we believe we can reach a broad audience and provide convenient access to our high-quality supplements.

Investment in Technology and R&D

Featuring an extensive selection of 37 herbal supplements, consisting of 16 proprietary formulations under our BioPrecision line and marketed with several brand labels (such as Best Doctor Formula, A Pure Herb, ZEN Life Herb, ACA Herb, and Dr. Herbal Well), and 21 legacy formulations of traditional single-herb or non-proprietary blends, DirecTCM leverages a data-driven knowledge library to assist healthcare professionals in identifying the most suitable supplements for overall wellness. In addition, DirecTCM provides and delivers the most up-to-date health information, tips on dietary supplements, and holistic plant ingredient knowledge, empowering healthcare providers to recommend supplements that further enhance patients’ well-being. We intend to continue investing in DirecTCM, refining methods for supplement recommendation. Ongoing improvements will incorporate richer data sets and aggregated outcomes to optimize the recommended regimens. We also continue to investigate and conduct R&D on holistic herbal ingredients,

Table of Contents

aiming for self-affirmed GRAS conclusion and research studies, to create our signature BioPrecision formulation that addresses today’s health demands, and we are actively funding ongoing studies investigating anti-cancer and anti-diabetes applications. See “— Research and Development — Research Studies” for details.

Plans for Growing Our Business

Leveraging on our in-depth experience in customized products and industry insights in the herbal supplements and accumulated understanding of market trends, we plan to enhance the variety of our products to better serve existing customers and attract new customers. We continue optimization on Amazon, TikTok, and other online platforms, such as Walmart.com and some third-party health sites to widen direct sales and expand multiple brand lines to address different consumer segments and price points, enabling cross-selling opportunities. Depending on regulatory pathways and local partnerships, we may explore export opportunities, especially in markets with high receptivity to holistic herbal supplement.

Corporate History and Structure

Farlong is a holding company incorporated on October 26, 2023 in the State of Nevada. Farlong has no substantial operations other than holding all of the outstanding share capital of its subsidiary, Longstar. Longstar was incorporated on November 22, 1999 in the State of California as Longstar International Inc. and changed its name to Longstar Healthpro, Inc. in January 2003.

In connection with this offering, we have undertaken a reorganization of our corporate structure in the following steps:

• On October 26, 2023, Farlong was formed in Nevada to serve as a holding company for Longstar.

• On December 27, 2023, Longstar, Farlong, and Longstar’s then sole stockholder, Karin Mei Huang, entered into a Share-for-Share Exchange Agreement (the “Share-For-Share Exchange”). Pursuant to the Share-For-Share Exchange, Karin Mei Huang exchanged all 2,000,000 shares of stock of Longstar which she then held, representing 100% of the outstanding shares of stock of Longstar, for 40,000,000 shares of Farlong’s common stock, which resulted in Longstar becoming a wholly-owned subsidiary of Farlong (with the one share of Farlong’s common stock outstanding prior to the exchange, which was owned by Longstar, being cancelled) and Karin Mei Huang becoming the 100% stockholder of Farlong.

• On January 31, 2025, immediately following the completion of the Share-for-Share Exchange, our then sole stockholder, Karin Mei Huang, entered into a Gift Receipt Agreement, pursuant to which she transferred all 40,000,000 shares of Farlong’s common stock that she owned to two family trusts, KML Family Trust and KMA Trust, for estate planning purposes.

Table of Contents

The following diagram illustrates our corporate structure as of the date of this prospectus and upon completion of this IPO based on a proposed number of 4,000,000 shares of common stock being offered, assuming no exercise of the underwriters’ over-allotment option.

____________

Notes:

(1) Represents 8,000,000 shares of our common stock held by KMA Trust as of the date of this prospectus. The Trustee of KMA Trust is Karin Mei Huang.

(2) Represents 32,000,000 shares of our common stock held by KML Family Trust as of the date of this prospectus. The trustees of KML Family Trust are Karin Mei Huang and her husband, Lipin Zeng.

For details of our principal stockholders’ ownership, please refer to the beneficial ownership table in the section captioned “Principal Stockholders.

Our Products

Our product offerings span various categories, including nutritional supplements, herb extracts, and herbal tea, with diverse sizes and concentrations to meet varied customer needs. For the three months ended December 31, 2025, we offered 68 SKUs of products. For the fiscal year ended September 30, 2025, we offered 68 SKUs of products, compared to 80 SKUs of products for the fiscal year ended September 30, 2024.

Historically, our catalog included both our proprietary formulations and a variety of third-party or non-proprietary products. Since 2024, we have shifted our focus to products based predominantly on our proprietary formulations, the BioPrecision formulations, and started to sell these products in July 2024, while phasing out traditional, non-proprietary products. The BioPrecision formulations or other supplements have not been reviewed or approved by the FDA. The products fall within the dietary supplement category and are marketed only for permissible structure/function or general wellness purposes. Below is a list of our BioPrecision formulations:

No.	BioPrecision Formulations	Description*
1	UTFREX	Supports urinary tract function and wellness
2	GoutREX	Assists in promoting healthy uric acid balance
3	WBM REX	Targets overall prostate wellness
4	CholesREX	Helps maintain healthy cholesterol levels
5	InnerpuREX	Aids in digestive comfort and regularity
6	LiverPure REX	Encourages healthy liver function

Table of Contents

No.	BioPrecision Formulations	Description*
7	Muscle REX	Helps ease muscle tension and discomfort
8	Muscle + Joint REX	Addresses both muscle and joint relief
9	IQ+Brain REX	Promotes cognitive clarity and function
10	Blood Sugar REX	Supports metabolism for balanced energy levels
11	Blood PressuREX	Encourages healthy blood pressure and circulation
12	Healthy Heart REX	Helps support cardiovascular function
13	CARDIO+FLOW	Promotes healthy blood flow and heart health
14	EYE HEALTH	Targets vision care and eye wellness
15	Calm Women	Addresses overall women’s wellness needs
16	Joint-Ease	Supports joint mobility and comfort

____________

* Our products are dietary supplements and have not been approved by the FDA and they are not intended to diagnose, treat, cure, or prevent any diseases.

We engage contract manufacturers to produce supplements according to our BioPrecision formulations in different sizes and concentrations to meet varied customer needs, resulting in multiple SKUs of products for each BioPrecision formulation. These supplements are made with all natural herbs, without any added vitamins or minerals, and the main ingredients in our supplements meet the self-affirmed GRAS determination standards.

Each BioPrecision formulation can generate several SKUs because we commercialize the same core blend under multiple customer-facing brands and, in some cases, in more than one package size or delivery form. For example, our Muscle REX formulation is marketed:

• as “Muscle Ease” under the Dr. Herbal Well practitioner brand (60-count capsules);

• as “Muscle REX” under the ZEN LIFE HERB consumer brand (60-count capsules);

• as “Muscle REX” under the A PURE HERB Amazon-focused brand (60-count capsules);

• as “Muscle REX” for ACA HERB franchise clinics (professional 60-count capsules); and

• as “Muscle REX” under the Best Doctor Formula line (professional 60-count capsules).

Similar multi-brand deployments apply to each of the other 15 BioPrecision formulations, resulting in two to seven active SKUs per formulation. The SKU count therefore reflects branding strategy and package configuration rather than differences in active-ingredient composition.

Products based on our BioPrecision formulations include:

• Cancer Support Supplements: White Button Mushrooms (WBMREx)

WBMREx, a cancer support supplement, is designed to support prostate, breast, and kidney health, strengthen the immune system including potential effects on immunomodulation, and promote overall wellness. WBMREx is composed of 70% White Button Mushroom (Agaricus bisporus) extract and 30% Notoginseng extract. WBMREx integrates the potential benefits of White Button Mushroom, which has been studied for its impact on prostate-specific antigen levels and immune function, with the anti-inflammatory properties of Notoginseng, making it a promising option for holistic wellness support. See “— Research and Development — Research Studies — Current Research Studies — White Button Mushroom” for details of the related research study.

• Diabetes Management Supplements: Blood Sugar Rex (BSRex)

BSRex, a diabetes management supplement, is formulated to help maintain healthy glucose levels and enhance insulin sensitivity and promote holistic metabolic health for individuals concerned about prediabetes, type 1 diabetes, or type 2 diabetes management. A key component in BSRex, the polygonum capitatum, is a core herbal extract historically used in holistic herbal supplement for managing blood sugar levels and improving metabolic function. See “— Research and Development — Research Studies — Current Research Studies — Polygonum Capitatum” for details of the related research study.

Table of Contents

• Inflammation Support Supplements: Muscle Ease REx (Rodgersia Sambucifolia Hemsl.)

Muscle Ease REx, our inflammation support supplement, is formulated to aid in post-exercise muscle recovery, reduce soreness, and support overall muscle health, flexibility, and movement. See “— Research and Development — Research Studies — Current Research Studies — Rodgersia Sambucifolia Hemsl.” for details of the related research study.

• Digestion Support Supplements: Farlong InnerPure

InnerPure, our detoxification and digestive health supplement, is formulated to support natural toxin elimination, promote digestive regularity, and aid in weight management. InnerPure is a combination of eight dietary ingredients used in supplements and in traditional Chinese medicine, and its ingredients have historically been used in China, Korea, Japan, India, and many other countries worldwide for a long time. See “— Research and Development — Research Studies — Past Research Studies — InnerPure” for details of the related research study.

• Cardiovascular Health Supplement: Farlong Notoginseng (Ginseng Plus)

Farlong Ginseng Plus, our cardiovascular health supplement, is formulated to support healthy cholesterol levels, promote blood pressure regulation, and enhance endothelial function. This supplement contains highly concentrated Panax notoginseng root extract, rich in bioactive components such as notoginsenoside, ginsenoside Rb1, and ginsenoside Rg1. Ginseng Plus is an extract of saponins from Panax notoginseng root, for use in human food and dietary supplements. See “— Research and Development — Research Studies — Past Research Studies — Notoginseng” for details of the related research study.

• Brain Health Support Supplements: Lifeflower Breviscapini

Lifeflower Breviscapini is an active flavonoid component extracted from Erigeron breviscapus to be used in our cognitive health supplement. Lifeflower Breviscapini is used as a direct human food and dietary supplement ingredient intended to be used in yogurt, nutritional bars, smoothies, and dietary supplements. It contains a standardized extract of Erigeron breviscapus, rich in scutellarin, a bioactive flavonoid with neuroprotective properties. See “— Research and Development — Research Studies — Past Research Studies — Breviscapini” for details of the related research study.

• General Health Supplements

Our general health supplements are designed to support overall wellness using natural herbal solutions, such as those supporting eye health, gut health, and urinary tract health.

Our Platform: DirecTCM.com

Our DirecTCM platform features an extensive knowledge library based on patient profiles, medical needs, and historical data, personalized supplement recommendations, and a seamless ordering and delivery system that works together to help provide efficiency and user satisfaction. As of December 31, 2025, our DirecTCM platform had approximately 30,000 pre-registered healthcare providers, of which 108 were active.

As of the date of this prospectus, through our DirecTCM platform, healthcare providers can access a comprehensive selection of 37 distinct finished-product formulations, consisting of 16 proprietary formulations under our BioPrecision line and marketed with several brand labels (such as Best Doctor Formula, A Pure Herb, ZEN Life Herb, ACA Herb, and Dr. Herbal Well) and 21 legacy formulations for traditional single herb or non-proprietary blends, which are being phased out as inventory is depleted, with no additional lots being manufactured after June 2024. See the table below for details.

Category	Formulations	Representative Brands	No. of SKUS as of the date of this prospectus
BioPrecision proprietary formulations	16	Best Doctor Formula and A Pure Herb	50
Legacy traditional/non-proprietary	21	FOCI Herbal	18
Total	37		68

Table of Contents

Health professionals can have supplements delivered directly to their patients or for in-office use, enhancing healthy lifestyles for the patients. With a wide range of our supplement products and three logistic warehouses to ensure the next-day delivery, our DirecTCM platform provides dedicated practitioner support, patient assistance, various contact options including email and phone support, and an interactive chat feature for instant help.

At the core of DirecTCM’s innovation is a data-driven knowledge library, designed to help healthcare professionals identify the most fitting products from an extensive selection of 37 formulations. The platform provides and delivers the most up-to-date health information, tips on dietary supplements, and holistic plant-ingredient knowledge, empowering practitioners to refine their recommendations and enhance overall patient wellness. By leveraging aggregated usage data and 26 years of sales trends, DirecTCM can refine supplement suggestions and highlight relevant educational resources and research articles, broadening healthcare providers’ understanding and application of TCM supplement principles in their practices.

One of the standout features of DirecTCM is its seamless integration of the ordering and fulfillment process within the clinical setting. Healthcare providers can select and order the recommended TCM and Farlong supplements together with their patients, facilitating immediate payment and eliminating any confusion about product selection or purchase locations. Following the in-clinic order, DirecTCM’s logistic operations work to see that patients receive their TCM and Farlong supplements at their doorstep within two business days or sooner. Healthcare providers across the United States can order supplements from Farlong, which are shipped directly to customers’ homes. To ensure rapid and reliable delivery, on June 7, 2024, we entered into a service agreement with a third-party logistics service provider, Armstrong Logistic Inc. (“Armstrong”), to warehouse our supplements in three strategically located facilities in California, Texas, and New Jersey. According to the service agreement, Armstrong agrees to provide the logistics and transportation services as we request for service fee rates specified in the service agreement. The service agreement will continue in full force and effect until terminated by either party with at least seven days’ written notice to the other party. This distribution network enables us to provide next-day delivery to most regions across the United States, ensuring our supplements reach customers as quickly as possible. Our agreement with the logistics service provider allows for flexibility and scalability, enabling us to adjust to demand fluctuations and maintain high fulfillment accuracy. Additionally, we leverage consumer data to collaborate with our logistics partner in optimizing logistics operations, enhancing delivery efficiency, and improving overall customer satisfaction.

Research and Development

Our R&D team brings over 26 years of experience in herbal knowledge and industry expertise. It is comprised of three individuals experienced in holistic herbal supplement pharmacology, molecular biology, herbal extraction processes, and data analytics, including Lipin Zeng, our founder and R&D Manager, who has 26 years of experience in herbal supplement formulations, with a focus on TCM-based on nutraceuticals, and Dr. Wei Xiang, who has 30 years of industry experience encompassing extraction technologies and data-driven product development in the holistic health sector. Our R&D team also work closely with external research institutions, including City of Hope for specialized projects.

Our R&D efforts focus on two primary areas, formulation development and DirecTCM platform development.

Formulation Development

Integrated Formulation Development Process

We maintain an integrated formulation development process that connects each phase — from research and formulation development through manufacturing and distribution — to real-time insights from healthcare providers and sales data via our DirecTCM platform.

• Gathering Insights: We rely on anonymized usage trends, reorder rates, and provider feedback from DirecTCM to shape product formulation goals and address evolving consumer needs.

• Close Collaboration with Manufacturers: Our research team refines formulations and provides exact specifications to cGMP-compliant contract manufacturers, ensuring product quality and consistency at scale.

• Quality Control and Production: Each production batch undergoes sample testing for quality, safety, and labeling compliance. Findings are used to promptly adjust formulations or processes, if necessary.

Table of Contents

• Real-Time Distribution Management: We integrate inventory and logistics data from our third-party warehouses with DirecTCM, so providers and patients receive accurate, up-to-date product availability and delivery information.

• Iterative Improvement: The DirecTCM platform’s sales metrics, alongside continuous feedback from healthcare providers, guide further product enhancements or distribution adjustments, allowing us to respond quickly and efficiently to market changes.

By synchronizing research, formulation, production, and distribution under DirecTCM’s data-driven framework, we can manage product quality and responsiveness to market demands in a unified, streamlined manner.

Our formulation development efforts are led by an internal R&D team composed of scientists and specialists with domain expertise in herbal supplement formulations. While they primarily drive product refinement, they also collaborate closely with external research partners and clinical investigators, such as City of Hope. Our internal team holds regular meetings with these external experts to review trial outcomes and translate findings into actionable improvements. This coordinated approach leverages both in-house capabilities and specialized external insights to develop and continuously enhance our BioPrecision formulations.

Research Studies

While results to date have not shown statistically significant outcomes, our ongoing and completed research studies play a crucial role in evaluating the safety and potential health benefits of our supplements. All current and past studies are fully funded through our internal R&D budget.

Voluntary, Non-FDA Research Studies for Dietary Supplements

Our White Button Mushroom, Polygonum capitatum, Rodgersia Sambucifolia, and other exploratory studies are investigator-initiated, dietary supplement studies conducted outside the FDA’s IND framework.

Purpose. These studies are designed to generate data on tolerability, dosage, and structure/function outcomes (such as to support healthy glucose metabolism), not to demonstrate disease treatment, cure, mitigation, or prevention.

Regulatory pathway. Because our products are marketed as dietary supplements, neither an IND nor FDA pre-market drug approval is required or being sought. We do, however, comply with:

• 21 C.F.R. Part 50 (Informed Consent) and Part 56 (Institutional Review Board (“IRB”) approval);

• applicable Good Clinical Practice guidelines; and

• any institutional or state-law human-research requirements.

Marketing prerequisites. Before commercial launch, we must ensure:

• our products’ ingredients are either (i) lawful dietary ingredients under Section 201(ff) of the FDCA or (ii) the subject of a New Dietary Ingredient notification submitted to the FDA at least 75 days before marketing;

• labeling and advertising with permissible structure or function claims and the required FDCA §403(r)(6) disclaimer; and

• manufacturing is performed in compliance with FDA dietary supplement cGMPs (21 C.F.R. Part 111).

No FDA evaluation of efficacy or safety has been done for these trials. The FDA does not review or approve these trials, nor does it pre-approve the finished supplements. As a common practice in our industry, we self-affirm that each ingredient is GRAS for its intended use, based on the published research reports issued by qualified experts.

Table of Contents

Current Research Studies

We are currently sponsoring three preclinical research studies at City of Hope, a California non-profit public benefit corporation, to evaluate the potential health benefits of certain botanical ingredients used in our dietary supplements. These studies are being conducted under research agreements dated October 7, 2024, and are in various early stages. While the full preclinical research study protocols have not yet been finalized, preliminary preparation activities are underway pursuant to initial research plans and draft protocols. Each research study is funded entirely through our internal R&D budget:

White Button Mushroom

On October 7, 2024, we entered into a research agreement with City of Hope. Under the research agreement, Dr. Shiuan Chen’s laboratory at City of Hope conducts a research study on White Button Mushroom extract samples provided by us through in vitro cell assays and in vivo animal assays. City of Hope is currently verifying that our dry powder lot is consistent with the material used in its research setting; no human clinical trials are being conducted under such research agreement. Once City of Hope is satisfied with the results of their internal testing, they will be able to proceed with preclinical trials with cells and animals.

Under the research agreement, we will make funding contributions of a total amount of $137,750 to City of Hope. Dr. Shiuan Chen’s laboratory at City of Hope will perform the research on the active components in White Button Mushroom for in vitro cell assays and in vivo animal assays of anti-cancer activity. All reports, findings, data and supporting documentation, in whatever form that are prepared or generated solely by City of Hope pursuant to the research agreement and that do not constitute Subject Inventions (as defined in the research agreement) will be the sole property of COH, while we hold a right of first negotiation to seek a license to certain inventions, if any. The agreement has a term from October 7, 2024 to October 7, 2027. Either City of Hope or we may terminate the agreement with notice if the other party commits a material breach not remedied within 30 days, or faces financial insolvency, bankruptcy, or similar debtor relief actions.

Polygonum Capitatum

On October 7, 2024, we entered a research agreement with City of Hope to conduct a preclinical research study regarding polygonum capitatum through in vitro cell assays and in vivo animal assays. No human clinical trials are being conducted under such research agreement. The botanical materials are being extracted and concentrated into a cGMP-compliant powder intended solely for laboratory research use. Work is limited to in vitro assays of bioactive fractions, material qualification, and related method development; initial activities for Polygonum Capitatum will focus on these in vitro evaluations. A start date for the laboratory phase has not yet been established.

Under the research agreement, we will make funding contributions of a total amount of $465,000 to City of Hope. City of Hope will perform the research on the active components in polygonum capitatum through in vitro cell assays and in vivo animal assays. All reports, findings, data and supporting documentation, in whatever form that are prepared or generated solely by City of Hope pursuant to the research agreement and that do not constitute Subject Inventions (as defined in the research agreement) will be the sole property of COH, while we hold a right of first negotiation to seek a license to certain inventions, if any. The agreement has a term from October 7, 2024 to December 31, 2028. Either City of Hope or we may terminate the agreement with notice if the other party commits a material breach not remedied within 30 days, or faces financial insolvency, bankruptcy, or similar debtor relief actions.

Rodgersia Sambucifolia Hemsl.

On October 7, 2024, we entered a research agreement with City of Hope to conduct a research study regarding Rodgersia Sambucifolia Hemsl through in vitro cell assays and in vivo animal assays. No human clinical trials are being conducted under such research agreement. The botanical materials are being extracted and concentrated into a cGMP-compliant powder intended solely for laboratory research use. Work is limited to in vitro assays of bioactive fractions, material qualification, and related method development; initial activities for Rodgersia sambucifolia Hemsl. will focus on these in vitro evaluations. A start date for the laboratory phase has not yet been established.

Table of Contents

Under the research agreement, we will make funding contributions of a total amount of $465,000 to City of Hope. City of Hope will perform the research on the Rodgersia Sambucifolia Hemsl through in vitro cell assays and in vivo animal assays. All reports, findings, data and supporting documentation, in whatever form that are prepared or generated solely by City of Hope pursuant to the research agreement and that do not constitute Subject Inventions (as defined in the research agreement) will be the sole property of COH, while we hold a right of first negotiation to seek a license to certain inventions, if any. The agreement has a term from October 7, 2024 to December 31, 2028. Either City of Hope or we may terminate the agreement with notice if the other party commits a material breach not remedied within 30 days, or faces financial insolvency, bankruptcy, or similar debtor relief actions.

With respect to our research studies conducted in the United States, while preliminary preparation activities, such as raw material refinement, are underway pursuant to initial research plans and draft protocols, the full research study protocols, including the primary and secondary endpoints, and the objective results of such research studies, including whether the trials meet their primary and secondary endpoints, have not yet been finalized or made available.

Past Research Studies

Completed research studies include studies on Notoginseng, InnerPure, and Breviscapine, which have shown beneficial effects on cardiovascular health, digestive support, and neuroprotection, respectively. The results of these studies have been published on EurekaSelect, a platform operated by Bentham Science Publishers, enhancing the credibility and scientific foundation of these products.

Statistical powering and p-values. Each of the three completed studies described below (Notoginseng, InnerPure, and Breviscapine) was designed as an exploratory structure/function dietary-supplement study. As such, the investigators did not conduct any prospective power calculations to ensure a predetermined level of statistical power (for instance, 80% at α = 0.05) for any primary or secondary endpoint. Except as noted below, no p-values were generated or reported for treatment-versus-placebo comparisons. The only p-values contained in the final study reports relate to baseline demographic comparisons among the randomized groups and were p = 0.04 for the overall Breviscapine trial population and p = 0.03 for the overall InnerPure trial population. The Notoginseng study report did not include any p-values in its baseline, safety, or outcome tables. Accordingly, all numerical results presented below (for instance, mean changes in LDL-C, cognitive-test scores, or body weight) should be interpreted as descriptive and hypothesis-generating, rather than confirmatory of statistically significant efficacy.

Notoginseng

A clinical trial evaluating the effects of Farlong Notoginseng on cholesterol and blood pressure was conducted by Marilyn Barrett, Ph.D. from Pharmacogosy Consulting, Inc. for us. The study was initiated in July 2016, and completed in June 2019. The research team conducted a randomized, placebo-controlled, double-blind study to assess the effects of this highly concentrated pharmaceutical grade notoginseng root extract on adults with elevated LDL-C and pre-hypertension. The results showed that Farlong Notoginseng was well-tolerated with no serious adverse events reported, and it observed improvements in exploratory endpoints in improving cardiovascular health markers.

The clinical trial titled “The Effect of Farlong NotoGinseng (Ginseng Plus) on Cholesterol and Blood Pressure” was conducted as a randomized, placebo-controlled, double-blind, parallel study aimed at evaluating the effects of Farlong NotoGinseng on cholesterol levels and blood pressure in human participants. Below is a brief description of the trial protocol and results:

Clinical Trial Protocol:

Jurisdiction: Conducted under the oversight of Health Canada.

Number of Participants: The trial initially enrolled 95 participants.

Study Design: It was an interventional Phase 2 study with two arms, the experimental group receiving Farlong NotoGinseng and a placebo group. Participants followed a 4-week therapeutic lifestyle change diet followed by a 12-week supplementation period.

Masking and Allocation: The study used a double-blind, randomized design.

Primary Purpose: Supportive care for people with elevated LDL-C and blood pressure.

Table of Contents

Primary Endpoint: The primary outcome measure was the difference in serum LDL-C from baseline to week 12 between the treatment and placebo groups.

Secondary Endpoints: Included differences in serum LDL-C at week 8, blood pressure at weeks 8 and 12, triglycerides at weeks 8 and 12, HDL-C at weeks 8 and 12, total cholesterol at weeks 8 and 12, and endothelial vasodilation at weeks 8 and 12.

Results:

Primary Endpoint Outcome: The mean change in serum LDL-C from baseline to week 12 was slightly greater in the placebo group (-0.12) compared to the treatment group (-0.07).

Secondary Endpoints Outcome: The results showed minimal changes across several secondary measures, often indistinguishable between treatment and placebo groups.

Serious Adverse Events: There were no serious adverse events reported. However, other adverse events were recorded, some including gastrointestinal disorders and fatigue. These were similar in both groups, with frequencies above 1%.

Conclusions: The trial did not show significant differences between treatment with Farlong NotoGinseng and placebo groups in the primary and secondary outcomes.

In summary, the clinical trial was completed in line with its protocol, overseeing jurisdiction in Canada. The results indicated no significant advantage of the supplement over placebo in reducing cholesterol or blood pressure within the trial duration.

InnerPure

In 2022, a clinical trial evaluating the safety and effectiveness of InnerPure as a natural herbal supplement for toxin release and digestive health was completed by M. Montgomery, Ph.D. and E. Masters, M.D. as commissioned by us. The research team conducted a study to assess the effects of this all-natural, vegan, non-GMO herbal formulation on 125 adults over a 30-day period. The results showed that InnerPure was well-tolerated with no negative impacts on any organs or systems measured, and no interactions, sensitivities, or side effects were observed or reported throughout the study period. Subjects taking InnerPure experienced significant improvements in constipation relief, with 100% of participants reporting healthy improvements in daily bowel movements by the conclusion of the study. Subjects taking InnerPure experienced an average weight reduction of four to five pounds, and 100% of participants reported improved digestive regularity.

Clinical Trial Protocol Overview for InnerPure Study

1. Number of Participants:

The clinical trial was conducted with 125 subjects, comprising 62 males and 63 females. Subjects were divided into four groups: three groups taking varying doses of InnerPure (one capsule twice daily, two capsules twice daily, and three capsules twice daily) and a placebo group with 25 subjects.

2. Study Design:

The trial was a double-blind, placebo-controlled study conducted over 30 days.

All participants were between the ages of 18 and 70.

3. Primary and Secondary Endpoints:

Primary Endpoint: To evaluate the safety and effectiveness of InnerPure in facilitating weight loss and improving bowel regularity without negative effects on body organs or systems.

Secondary Endpoints: Assess changes in blood test markers to ensure no adverse effects, including liver enzymes (AST, ALT, and APL), urine parameters such as color and pH, and complete blood counts (WBC, RBC, and PLT).

Table of Contents

4. Adverse Events:

No serious adverse events were reported during the study. All subjects tolerated InnerPure well, and there were no reported interactions, sensitivities, or side effects.

5. Objective Results:

All subjects on InnerPure reported improved bowel movements by Day 30.

Participants in the InnerPure groups saw an average weight loss of 4-5 pounds.

No negative impacts on liver function or other organ systems were observed through blood and urine tests.

Blood markers remained within normal ranges.

6. Jurisdiction:

Jurisdiction and regulatory compliance. The final study report provided by the principal investigators does not specify the physical location(s) of the clinical site(s). Notwithstanding the absence of site addresses, the investigators expressly certified in the report that (i) all subjects gave written informed consent; (ii) the study was conducted using a double-blind, randomized, placebo-controlled design; (iii) the study product was manufactured in an FDA dietary-supplement cGMP — certified facility and tested by an independent, third-party laboratory; and (iv) the trial adhered to Good Clinical Practice guidelines. Based on these certifications and our contractual requirements that the investigators comply with 21 C.F.R. Parts 50 and 56 and all applicable human-research laws, we believe the study met the regulatory and ethical standards customarily applied to exploratory dietary-supplement trials in the United States and comparable jurisdictions.

In conclusion, the study met its primary and secondary endpoints by demonstrating that InnerPure can promote weight loss and improve bowel regularity without adverse health effects. Further studies were recommended for more extended periods to assess long-term benefits.

Breviscapine

In 2022, a clinical trial evaluating the efficacy of Lifeflower Breviscapini as a supplement for cognitive function enhancement was completed by N. Harris Psy.D. and J. Reinhart DO as commissioned by us. The research team conducted a study involving 160 subjects over 90 days to assess the effects of this standardized Erigeron Breviscapus extract (95% Scutellarin) on cognitive performance in adults. The results showed that Lifeflower Breviscapini was well-tolerated with no negative impacts on any measured organs or systems, and no side effects or sensitivities were reported throughout the study period. The MemTrax test scores improved from 78%-79% at baseline to 80%-84% after 90 days of supplementation (with higher doses showing greater improvements), moving participants from the “needs improvement” category into the “normal” range.

Clinical Trial Protocol Summary for Lifeflower Breviscapini

Objective:

The primary objective of the clinical trial was to evaluate the effects of Lifeflower Breviscapini on improving cognitive function, including long and short-term memory, concentration, and clarity of thinking in healthy individuals over a 90-day period.

Participants:

Total Participants: 160 subjects

Age Range: 18 to 70 years

Gender Ratio: 3 males to 1 female (107 males, 53 females)

Table of Contents

Study Design:

This was a double-blind, randomized, placebo-controlled, parallel-group study.

Participants were divided into four groups:

Group 1: Placebo group (40 subjects taking rice powder capsules);

Group 2: 100mg of Lifeflower Breviscapini, twice daily (40 subjects);

Group 3: 200mg of Lifeflower Breviscapini, twice daily (40 subjects); and

Group 4: 400mg of Lifeflower Breviscapini, twice daily (40 subjects).

Endpoints:

Primary Endpoint: Improvement in cognitive function measured by Mem Trax, MMSE (Mini-Mental State Examination), and MoCA (Montreal Cognitive Assessment).

Secondary Endpoints: Blood biomarkers for safety evaluation, including RBC, WBC, PLT, AST, ALT, ALP, GGT, creatinine, HbA1c, sodium, potassium, and calcium levels.

Procedures:

Participants were assessed at Day 0, Day 30, Day 60, and Day 90.

Biomarkers in the blood and cognitive tests were used to measure safety and effectiveness.

Compliance was checked via bi-weekly phone calls, and subjects maintained current lifestyle habits throughout the study.

Results:

All cognitive test scores showed improvement across groups taking the active product.

Group 2, 3, and 4 exhibited significant improvements in Mem Trax, MMSE, and MoCA scores from Day 1 to Day 90.

Biomarker results indicated no adverse impact on participants’ health across any groups.

No serious adverse events or side effects were reported.

Jurisdiction:

Conclusion:

The study suggested potential positive impacts on HbA1c levels, warranting further long-term studies. The trial met its primary and secondary endpoints, indicating potential benefits in mental health and safety over the trial period.

Table of Contents

DirecTCM Platform Development

We have undertaken a series of in-house research and development initiatives to improve the DirecTCM platform:

• Data Ingestion and Integration: We have established pipelines to aggregate anonymized usage data (for instance, dosage patterns and adherence rates) alongside decades of sales records. This initiative requires custom software architecture and rigorous testing to ensure compatibility, security, and scalability.

• Logistics and Inventory Integration: We integrate DirecTCM with our third-party logistics partner’s system, creating a real-time data exchange of shipping times and stock levels. The R&D effort covered application programming interface development, data mapping, and performance optimization to ensure smooth, continuous updates.

• User Interface & Experience Upgrades: Based on feedback from healthcare professionals, we improve the DirecTCM dashboard for ease of navigation and more concise presentation of supplement information. Ongoing R&D investments focus on refining interface elements, load times, and search functionality.

• Knowledge Library Expansion: We curate a more robust “knowledge library” within the platform, compiling verified references on herbal supplements and historical outcomes. This R&D project requires additional database structuring and content validation to ensure healthcare providers can access the latest, clinically relevant materials.

• Security and Compliance Reviews: We periodically conduct internal reviews of data handling protocols, ensuring anonymized usage data remains private and adheres to relevant regulatory or data-protection standards.

By implementing these technology-focused R&D initiatives, our DirecTCM platform can more effectively collect, analyze, and present information that benefits both healthcare providers and the Company’s broader strategy, all while maintaining a secure and scalable infrastructure. This ongoing effort ensures DirecTCM remains responsive to user needs, continuously incorporating new modules and updates to improve performance, reliability, and utility for clinical practice.

Manufacturing Process

Rather than manufacturing our products in-house, we develop product formulations and engage specialized cGMP-compliant contract manufacturers to produce our proprietary supplements according to our BioPrecision formulations, which supplements we then market and distribute. We typically enter into purchase agreements or purchase orders with the manufacturers with a fixed period to engage them to produce our proprietary supplements. According to the purchase agreements or purchase orders, we provide our formulations and specifications requirements to the contract manufacturers. These certified cGMP facilities handle actual supplement production, encapsulation, blending, and packaging. They also ensure compliance with FDA standards or other local regulatory requirements, and maintain consistent batch quality, and we enforce strict specifications and quality checks, often integrating our own R&D team for final product reviews. During the three months ended December 31, 2025, we engaged two contract manufacturers. During the fiscal years ended September 30, 2025 and 2024, we engaged two contract manufacturers for each period.

Distribution Channels

Starting from the fiscal year ended September 30, 2024, we have adopted diverse distribution channels to sell our products to our customers through online and offline distribution initiatives. By diversifying our product lines and distribution channels, we aim to capture a wide audience, increase market penetration, and boost overall sales revenue. As of the date of this prospectus, our distribution channels consist of (i) our DirecTCM platform; (ii) online stores through our official website and various e-commerce websites, such as Amazon.com and Walmart.com; and (iii) B2B wholesale in the clinics or medicine centers, and OEM specialist sales lines, such as the franchise centers.

Table of Contents

Our Brands

We have strategically designed our products to maximize sales revenue through various brands and distribution channels:

“Best Doctor Formula” and “Dr. Herbal Well”: These brands are designed for healthcare professionals, such as physicians, integrative health providers, and nutritionists to prescribe and sell to their patients through our DirecTCM platform or health providers’ in-office channels, ensuring targeted distribution. These brands cater to clinics and integrative medicine practices, where efficacy and evidence-based formulations are paramount.

“ACA Herb”: Our OEM brand “ACA Herb” is specifically developed for the Acupuncture Corporation of America (“ACA”) Acupuncture and Wellness Center franchise stores. ACA focuses on high-quality acupuncture and formulation-based treatments across North America, making ACA Herb a natural extension for clinic-dispensed herbal supplements.

“ZENLife Herb” and “A Pure Herb”: These brands are designed for our OEM white-label customers and are optimized for ecommerce platforms such as Amazon. We entered into manufacture and sale agreements with these two OEM brands respectively. The optimization includes competitive pricing strategies tailored to online marketplaces, label designs that meet ecommerce platform requirements, and packaging optimized for efficient shipping and handling. These cooperations help ensure the products are ready for seamless integration into ecommerce channels and provide a high-quality experience for online consumers.

Logistics and Supply Chain

To ensure rapid and reliable delivery, we use three strategically located logistics warehouses in California, Texas, and New Jersey operated by our logistics service provider Armstrong to geographically cover the west coast, the Midwest, and the east coast markets. This distribution network enables us to provide next-day delivery to most regions across the United States, ensuring our supplements reach patients as quickly as possible. Our custom logistics system is designed for flexibility and scalability, allowing us to adjust to demand fluctuations and maintain high fulfillment accuracy. In addition, we leverage consumer data to continuously optimize our logistics operations, enhance delivery efficiency, and improve overall customer satisfaction.

Sales and Marketing

Farlong is adopting a multifaceted sales strategy that emphasizes scalability and differentiation across distribution channels. This approach is designed to optimize market penetration and revenue growth through targeted online and offline sales initiatives, alongside strategic international expansion. Additionally, our DirecTCM platform is being enhanced with multilingual support and localization features tailored for Asian and European markets. We also have a sales and marketing team to support high-volume clinics or distributors with training, promotional materials, and ordering assistance.

We market our supplements products under the brands Dr. Herbal Well, Best Doctor Formula, and various OEM lines on our DirecTCM platform and some leading e-commerce platforms, such as Amazon.com and Walmart.com. This strategic online presence aims to capture a significant share of the digital marketplace.

Our Customers

As the date of this prospectus, our customers include (i) healthcare providers on our DirecTCM platform or through wholesale B2B channels, (ii) end-consumers purchasing online through e-commerce platforms like Amazon and TikTok, and (iii) some OEM or white-label partners who rebrand our supplements. We typically enter into formal sales contracts or standard purchase orders with our healthcare providers or clinics customers, integrated with the DirecTCM platform for streamlined reordering. The standard sale contract specifies the ordering and delivery details, and includes a warranty and liability term, and a general indemnification term. We also enter into tailored manufacturing sales contracts with our OEM partnership customers, which contracts include terms regarding volume commitments, labeling or packaging specifications, and negotiated pricing structures. Under the manufacturing sales contract, we agree to manufacture the supplements in accordance with the quality standards and specifications mutually agreed upon by both parties, and the OEM partnership customer shall be responsible for the promotion, marketing, and sale of the supplements on the e-commerce website or other channels.

Table of Contents

For the three months ended December 31, 2025 and for the fiscal years ended September 30, 2025 and 2024, we had 150, 163, and 199 customers, respectively, principally distributors, healthcare providers, and e-commerce retailers. The number of customers includes e-commerce platforms, Amazon and TikTok, with each platform counted as a single account for analysis purposes. Our DirecTCM platform was officially launched in May 2025 and it had 108 active healthcare providers as of December 31, 2025. For the three months ended December 31, 2025, Long Far Herbal Medicine Mfg. (HK) Limited accounted for 10% of our total revenue. For the fiscal year ended September 30, 2025, one customer, Zenlife, accounted for 21% of our total revenue. For the fiscal year ended September 30, 2024, two customers, namely Zenlife and Dr. Chunhua Cui, accounted for 25% and 12% of our total revenue, respectively.

Our Vendors

We source herb extracts and ingredients from herbal extract companies specializing in holistic herbal and botanicals and other nutraceutical components. We generally enter into purchase orders with these vendors, which lay out the general terms of our relationship, such as order of goods, delivery and acceptance, processing of returns, and terms and conditions of payments, among other things.

We rely on specialized cGMP-compliant contract manufacturers to produce our proprietary supplements. We also partner with a third-party logistics service provider for warehousing and next-day fulfillment. See “— Manufacturing Process” and “— Properties” for our arrangements with contract manufacturers and the third-party logistics service provider.

For the three months ended December 31, 2025, our three largest vendors, Zenlife, TCM Product Inc, and Yunnan Panlong Trading accounted for 73%, 16%, and 11%% of our total purchases, respectively. For the fiscal year ended September 30, 2025, our five largest vendors, Kunming Aoqun, TCM Product Inc, Zenlife, Yunnan Panlong Trading, and Lonza Greenwood LLC accounted for 44%, 18%, 15%, 11%, and 10% of our total purchases, respectively. For the fiscal year ended September 30, 2024, two vendors, Kunming Aoqun and TCM Product Inc, accounted for 83% and 11% of the Company’s total purchases, respectively.

Our Industry and Opportunity

Global Market for Dietary Supplement

Rising prevalence of chronic disorders, including obesity, diabetes, heart disease, and cancer, and the busy lifestyles and resultant changes in dietary patterns of consumers are among the key factors driving consumption of dietary supplements worldwide. Manufacturers are continuously introducing novel products and formulations targeting specific consumer needs and preferences, such as weight management, sports nutrition, and brain health, among others. Consumers are increasingly made aware of such products and their benefits through effective marketing campaigns, influencer endorsements, and social commerce.

FARLONG HOLDING Corp S-1/A